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Professor Joseph Ackerman, Chair 
Professor Dmitriy Yablonskiy  
 
Alzheimer’s disease (AD) affected approximately 48 million people worldwide in 2015. Its 
devastating consequences have stimulated an intense search for AD prevention and treatment. 
Clinically, AD is characterized by memory deficits and progressive cognitive impairment, 
leading to dementia. Over the past two to three decades, researchers have found that amyloid-
beta (Aβ) plaques and neurofibrillary tau tangles occur during a long pre-symptomatic period 
(preclinical stage) before the onset of clinical symptoms. As a result, identification of the 
preclinical stage is essential for the initiation of prevention trials in asymptomatic individuals. 
Currently, Positron Emission Tomography (PET) imaging with injected 11C or 18F containing 
radiotracers (e.g., Pittsburgh compound B, PiB or florbetapir-fluorine-18, 18F-AV-45) is widely 
used to detect amyloid deposition in vivo and to identify this preclinical stage. However, PET 
scans are time consuming (about 1 hour), require injection of a radiotracer, thus, exposing the 
patient to ionizing radiation. After the preclinical stage, AD patients begin to show clinical 
symptoms, referred as a very mild or mild AD group. Post-mortem studies show that neuronal 
damage is the most proximate pathological substrate of cognitive impairment in AD compared 
 x 
 
with amyloid and tau deposition. Thus, a diagnostic tool is needed for detection of neuronal loss 
in vivo. As a faster, non-invasive, and radiation free imaging technique, Magnetic Resonance 
Imaging (MRI) plays an important role in the diagnosis of cognitive diseases. Conventional MRI 
yields superb definition of brain anatomy and structure and provide important volumetric 
information (e.g., brain atrophy). However, conventional MRI cannot provide microstructural 
and functional insight into the pathology of AD.  
The approach developed in Yablonskiy’s lab is based on the Gradient Echo Plural Contrast 
Imaging (GEPCI) protocol, which provides quantitative in vivo measurements of transverse 
relaxation properties of the tissue water 1H spins as determined from the gradient echo MRI 
signal. The measurements are corrected for macroscopic magnetic field inhomogeneity effects 
and physiologic-motion-driven fluctuations in magnetic field as these are the major artifacts 
present with the gradient echo technique. The principal relaxation property used in this 
dissertation is the tissue-specific transverse relaxation rate constant, R2*. The R2* value reflects 
the microscopic and mesoscopic magnetic field inhomogeneities rising from the complex tissue-
water-environment within the human brain. In turn, changes in R2* reflect changes in the 
tissue’s microscopic and mesoscopic tissue structure.  
However, because of the presence of the cerebral blood vessel network, the magnetic-
susceptibility-driven blood-oxygen-level dependent (BOLD) effect also makes a significant 
contribution to R2*. A previously developed approach, quantitative BOLD (qBOLD), allows the 
separation of R2* into a tissue specific R2t* without blood vessel effects and the BOLD 
component. Quantifying the BOLD component allows the calculation of cerebral hemodynamics 
parameters, such as oxygen extraction fraction (OEF) and deoxygenated cerebral blood volume 
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(dCBV). These parameters (R2*, R2t*, OEF, dCBV) describe structural and functional 
properties of tissue at the microstructural level in the human brain.  
In the study of normal aging, quantitative GEPCI measurements showed that R2t* increases with 
age while hemodynamic parameters, i.e., relative OEF and dCBV remain constant in most 
cerebral cortical regions. The comparison between quantitative GEPCI measurements and 
literature information suggest that (a) age-related increases in the cortical R2t* mostly reflect the 
age-related increases in the cellular packing density (or neuronal density); (b) regions in a brain 
characterized by higher R2t* contain a higher concentration of neurons with less developed 
cellular processes (dendrites, spines, etc.); and (c) brain regions characterized by lower R2t* 
represent regions with lower concentration of neurons but more developed cellular processes.   
In the Alzheimer study, R2* and R2t* together demonstrated significant differences among the 
normal, preclinical and mild AD groups. First, the results uncovered strong correlations between 
R2* and Aβ deposition measured by the PiB PET-tracer in several cortical regions (e.g., medial 
temporal lobe and precuneus). This finding indicates that R2* may be a potential surrogate 
marker for Aβ deposition. The strongest correlation was found in the medial temporal lobe 
(MTL), particularly in the parahippocampal cortex, which can be used to distinguish the normal 
and preclinical groups.  
Second, R2t* in the hippocampus, which characterized the hippocampal cellular integrity 
demonstrated much stronger correlations with psychometric tests than volume quantification of 
hippocampal atrophy. Importantly, decreased R2t* characterizing cellular damage was detected 
even in the hippocampal areas not affected by atrophy. In addition, R2t* significantly decreased 
in the mild AD group but was preserved in the preclinical group compared with the normal 
 xii 
 
group. These results indicate a significant cellular density decrease in the mild group but not in 
the preclinical group, which is consistent with previous histological studies. 
In summary, GEPCI provides a new approach for evaluation of AD-related tissue pathology in 
vivo in the preclinical and early symptomatic stages of AD. Since MRI is widely available 
worldwide and does not require radiation exposure, it provides the opportunity to obtain new 
information on the pathogenesis of AD and for pre-screening cohorts (stratification) for clinical 
drug trials.  
 1 
Chapter 1: Introduction to Gradient Echo 
Plural Contrast Imaging (GEPCI) 
 
1.1 MRI Basics 
1.1.1 Nuclear Spins 
In classic physics, a rotating object possesses a property known as angular momentum. The 
angular momentum is related to the object’s size, mass, and rotational velocity. However, in 
quantum mechanics, spin or spin angular momentum is an intrinsic property of atomic and 
subatomic particles. The quantum spin number s is quantized, which means that it only takes 
values of N/2, where N is a non-negative integer. So the spin angular momentum S of any 
physical system is also quantized with the spin quantum number s and Planck’s constant h: 
                                                           ( 1)
2
h
S s s

   .                                                      (1.1) 
The component of S along any direction is calculated as follows: 
                                                , { , 1,..., 1, }
2
i i i
h
S s s s s s s

      .                                        (1.2) 
Thus, we see that S has 2s+1 components in different directions.  
Due to the intrinsic spin, particles also have an intrinsic magnetic moment µ, which is the 
product of the gyromagnetic ratio  and the spin angular momentum S: 
                                                                         S   .                                                           (1.3) 
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The magnetic moment is used to describe how a small magnetic dipole (or current loop) interacts 
with an external magnetic field. The magnetic energy of a particle (E) is the dot product of its 
magnetic moment and the external magnetic field (B0):  
                                                                        0E B    .                                                    (1.4) 
Let us take the proton as an example, because it is the most common source of MRI signal. The 
quantum spin number s of a proton is ½. So there are 
1
2 1 2
2
    components of the spin angular 
momentum S. Assume that B0 is applied along the Z direction and substitute µ with  and S. Then 
the magnetic energy (E) of protons is written as follows: 
                                                                
0 0
4
z
h
E S B B 

    .                                         (1.5) 
We see that proton has two energy states in the presence of an external magnetic field (also 
referred to spin-up and spin-down). The energy difference between the two states is written as 
follows: 
                                                                         
0
2
h
E B

  .                                                 (1.6) 
According to Boltzmann statistics, the population ratio of the spins in the two states is calculated 
as follows: 
                                    
0( ) exp( ) exp( )
( ) 2
h BPopulation anti parallel E
Population parallel kT kT


 
     ,               (1.7)    
where k is the Boltzman constant and T is the absolute temperature. At body temperature in a 
field of 3.0 Tesla, the population ratio is nearly 1. Only a small excess on the order of 1 per 106 
 3 
spins is expected to be found in the lower energy state. Fortunately, in a biological environment, 
there is a large enough population of 1H to provide a sufficient MRI signal. 
1.1.2 Free Induction Decay (FID) Signal 
For convenience, in the field of magnetic resonance imaging, nuclear spins are usually 
considered as the analogue of spins in classical physics. Thus, spins are considered to precess 
around the magnetic field B0. The frequency of the precession is known as the Larmor frequency: 
                                                                        0 0B   .                                                         (1.8)    
We see that ΔE is proportional to the Larmor frequency as well, which is the frequency required 
for the transition of the two energy states. Spins at equilibrium produce a net magnetization M0 
along B0. It is convenient to use this net magnetization M0 to interact with B0 instead of 
considering all the spins.  
To understand the formation of the MRI signal, let us define a space with X, Y, and Z directions. 
The external magnetic field, B0, is along the Z direction. In reality, the receiver coils are placed 
on the transverse plane to detect the currents generated by the precession of the transverse 
magnetization around B0. Thus, an electromagnetic radio frequency (RF) pulse with a nearly 
Larmor frequency is usually applied perpendicular to B0 to flip M0 towards the XY plane by a 
certain angle. At the quantum level, nuclear spins absorb the energy from the RF pulse with 
Larmor frequency and are excited to the higher energy state. After the RF pulse is turned off, two 
independent relaxations, T1 and T2* relaxations, occur simultaneously. A T1 relaxation is also 
called a thermal relaxation, in which the spins release the absorbed energy to the surrounding 
environment and return to the thermal equilibrium. As a result, the Z component (Mz) of the 
magnetization grows back to M0 over time. For example, consider a 90 RF pulse that is applied 
 4 
to flip M0 onto the transverse plane. After the RF pulse is turned off, Mz changes over time (t) in 
accord with the following equation: 
                                                         0 1(1 exp( / ))zM M t T     .                                             (1.9)    
In the meantime, the nuclear spins start to dephase on the transverse plane due to magnetic-field 
inhomogeneities—a process that is characterized as a T2* relaxation. The inhomogeneities 
include irreversible and reversible parts. The irreversible part is caused by the fluctuating 
magnetic fields generated from the spin-spin interactions—a process that is characterized as a T2 
relaxation. There are three sources that induce a microscopic inhomogeneous field on the atomic 
level: electron spin, electron orbital current, and nucleus spin. The reversible part is mainly due 
to external fixed inhomogeneities, such as imperfect magnet and field distortion at the air/tissue 
interface. The transverse magnetization (Mx,y) changes over time t, as in the following equation: 
                                              
*
, 0 2 0 0exp( / ) cos( )x yM M t T t       .                                  (1.10) 
Due to T2* relaxation, the transverse magnetization Mx,y decays over time, which is referred to 
as a free induction decay (FID) signal. 
1.1.3  Gradients, Gradient Echo Sequence and K-Space  
Although the FID can be measured, the signal comes from the whole object, and the signal at 
each location on the object needs to be computed. Thus, a constant magnetic field gradient is 
applied so that the overall magnetic field is linearly dependent on the location. For example, 
consider a one-dimensional situation: The homogeneous magnetic field B0 is along the X 
direction, and a gradient Gx is applied along the same direction. Then the distribution of the 
overall magnetic field is linearly dependent on the location x:  
 5 
                                                                    0 xB B G x    .                                                  (1.11)    
Accordingly, the precession frequency is dependent on the location x: 
                                                               0 xB G x         .                                           (1.12) 
As a result, the location of a proton is encoded by its precession frequency, which is known as 
frequency encoding. Frequency encoding provides a one-dimensional projection of spin density. 
To get a two-dimensional image, we need to apply a gradient (Gy) in the orthogonal direction 
(e.g., the Y direction) to the frequency-encoding gradient, which is known as the phase-encoding 
gradient. The phase-encoding gradient is applied after the RF pulse and before the frequency-
encoding gradient for a short period (on the order of millisecond). In this short duration, spins 
accumulate a certain amount of phase to encode the location along Y direction. Likewise, a 
three-dimensional image is created by adding an additional phase-encoding gradient along the Z 
direction. The location along the Y and Z directions is encoded by the accumulated phase, while 
the location along X is encoded by the precession frequencies. 
Because all of the MRI experiments in my projects are based on the gradient echo (GE) 
sequence, a diagram of the sequence to obtain a 2-D MRI image is shown below in Figure 1.1: 
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Figure 1.1 A diagram of the gradient echo sequence to obtain a 2-D MRI image. 
 
First, a frequency-selective RF pulse is applied to flip the original magnetization M0 by a certain 
angle (30 in GEPCI experiments). Concurrently, a slice-selective gradient is applied along the 
slice direction (the Z direction) to excite spins in a targeting slice. However, the gradient brings 
magnetic-field inhomogeneity and causes unwanted dephasing of the spins, which starts in the 
middle of RF pulse duration. Thus, a rewinding gradient with exactly half the power of the slice 
gradient follows to refocus the spins. Then a single step of the phase-encoding gradients is 
applied over a certain duration to let the spins accumulate spatially dependent phase along the Y 
direction. Next, a pre-rewind gradient is applied over exactly half of the read-out duration (t/2) 
along the X direction. Then the readout gradient is turned on to refocus the spins and form an 
echo at the gradient echo time (TE). In the meantime, the signal receiver is also turned on to 
sample signals over time. The signal sampled during one read-out gradient is a single line of the 
k-space. The same procedure is repeated at every time of repetition (TR) to fill in lines in k-
space. Notice that, in every repetition, the phase-encoding gradients move to the next step (a new 
 7 
gradient). When all of the repetitions are completed, the phase-encoding gradients move to the 
last step and the k-space is fully filled. To obtain a 3-D image, replace the slice-selective gradient 
with an additional phase-encoding gradient. 
Assume that there is no other magnetic-field inhomogeneity except for the gradients along the 
XYZ directions. The signal at each point during the read-out sampling can then be written as, 
               
~
0
, ,
( ) ( , , ) exp[ ( ) ]x y y z z
x y z
S t x y z i TE t i G xt i G yt i G zt dxdydz           ,         (1.13)          
where ( , , )x y z  is the “ideal” signal at location (x, y, z) on the object. Notice the time is 
represented as TE+t, where t is the time during GE acquisition (t is zero at the center of the GE). 
To compute ( , , )x y z , we substitute 2 ( , , )j j jk G t j x y z   , and the equation is rewritten as 
follows: 
          
~
0
, ,
( , , ) ( , , ) exp[ ( ) 2 2 2 ]x y z x y z
x y z
S k k k x y z i TE t k x k y k z dxdydz           .      (1.14) 
~
( , , )x y zS k k k  is the so called “k-space”. In GEPCI experiments, the k-space at each slice is 
comprised of 256 lines, and each line is comprised of 256 points. Notice that k-space is the 3D 
Fourier transform of the signal in the image domain ( , , )x y z . So inverse Fourier transform is 
applied to the k-space data to generate ( , , )x y z : 
                                                             
~
1( , , ) [ ( , , )]x y zx y z FT S k k k
  .                              (1.15) 
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But in reality, the sampling during read-out duration is discrete. As a result, the signals in both 
the k-space and the image domain are stored in voxels ( , ,x y zk k k  are integers). The signal within 
a voxel is considered an integral over the locations. Thus, a fast Fourier transform (FFT) 
algorithm is used in this case. Then the transformed image also stores signals in voxels. Different 
notations would be used to distinguish the signal at a continuous point and a voxel.  
1.2  Gradient Echo Plural Contrast Imaging (GEPCI)  
The GEPCI technique is based on, (i) a 3D gradient echo (GE) sequence with multiple gradient 
echoes (currently available from most MRI scanner manufacturers), and (ii) a set of post-
processing algorithms (1-6) that make it possible to generate images and quantitative maps with 
several contrasts that reflect the anatomic and microstructural properties of biological tissue. 
Importantly, all these GEPCI images are simultaneously acquired and are thus naturally co-
registered.  
1.2.1  MRI Data Acquisition  
The scans were made in a 3T PET-MR scanner (Siemens, Erlangen, Germany). A 3D multi GE 
sequence and a 12-channel phased-array head coil were used to obtain the data. The sequence 
parameters were as follows: resolution 1×1×2 mm3 (read, phase, slab), FOV 256 mm×192 mm, 
repetition time TR = 50ms, flip angle 30°, 10 gradient echoes with first gradient echo time TE1 = 
4 ms, and echo spacing ∆TE = 4ms. An additional phase stabilization echo (the navigator data) 
was collected for each line in k-space to correct for image artifacts due to the physiological 
fluctuations (4). The total acquisition time of GEPCI was 11 mins 30s.  
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1.2.2   Image Construction by Combining Multi-channel Data 
Notice that MRI data is collected through a 12-channel RF coil. After the multi-channel data was 
transformed from k-space to the image space by using inverse FFT, it was combined using the 
following algorithm (2): 
                               
2
1 2
1 1
1
( ) ( ) ( );
M M
ch ch
n ch n n ch ch
ch chch
S TE S TE S TE
M
  


 
   

  ,                  (1.16)     
where the sum was taken over all M channels (ch), nS  represents the signal at the nth voxel in 
the image domain (
~
S is the signal in the k-space), S  denotes complex conjugate of S , ch  are 
weighting parameters, and ch  are noise amplitudes (r.m.s.) outside the human skull on the MRI 
image. Index n corresponds to the voxel position. This algorithm allows for the optimal 
estimation of quantitative parameters (2, 7) and removes the initial phase incoherence among the 
channels (2).  
Notice that we previously used ( , , )x y z to denote the “ideal” signal at location (x, y, z) in the 
image domain. Herein, we use nS  to represent the signal at a single voxel. It is not “ideal” 
because of the effects of magnetic inhomogeneity. 
1.2.3  Voxel Spread Function for Macroscopic Field Inhomogeneity Effects 
Although gradient echo sequence is fast, the images can be adversely biased by macroscopic 
magnetic-field inhomogeneities. So ( )nS TE  includes not only the “ideal” signal within the voxel, 
but also the signal due to magnetic-field inhomogeneities. Yablonskiy’s lab reanalyzed a basic 
theory of gradient echo MRI signal formation and developed a voxel spread function to model 
the signal behavior in the presence of macroscopic magnetic-field inhomogeneities (3). For 
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example, Figure 1.2 shows that this function can significantly reduce artifacts on in vivo MRI 
images due to the macroscopic magnetic-field inhomogeneity at the air/water interface. 
 
 
 
 
 
 
 
Figure 1.2 Example of an R2* map corrected with and without the voxel spread function from a 
healthy individual. Obviously, huge artifacts appear on the uncorrected R2* map on the left due 
to the macroscopic magnetic-field inhomogeneity at the air/water interface (around nose). The 
artifacts disappeared (right image) after the voxel spread function was applied.  
 
The theory of this algorithm is briefly introduced here. Consider a 1-dimensional GE experiment. 
In the presence of an inhomogeneous magnetic field ( )b x , the MRI signal during the readout 
period t is expressed in the following equation: 
                 
~
0( ; ) ( ; ) exp[ 2 ( )( ) ( )]
2
x x
x x x
S k TE x TE ik x i b x TE t i x dx
k G t
   
 
      

 ,                    (1.17)       
where TE is the gradient echo time, x is the location in the image space, kx is a voxel in k-space, 
xG is the read-out gradients, xt is the duration of the gradient, ( ; )x TE  is the “ideal” signal at the 
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continuous location x in the absence of magnetic-field inhomogeneities, and 0 ( )x is the signal 
phase shift at TE=0 (which results mainly from RF field inhomogeneities). Notice again that the 
time is represented as TE+t, where t is the time during GE acquisition (t is zero at the center of 
the GE).  
The goal is to compute the “ideal” signal in a voxel, so we need to convert the continuous 
equation to a discrete equation on the voxel level. Because the scale of macroscopic field 
inhomogeneities is much larger than the size of a voxel, the distribution of ( )b x  and 0 ( )x  in the 
mth voxel is represented as a linear approximation: 
                                                                   
0 0,
( )
( )
m m mx
m mx
b x b g x
x x  
 
 
 ,                                          (1.18)       
where mb  and 0,m  are constants within the mth voxel but vary over voxels, and where mxg and 
mx  are the background gradients within the mth voxel. The “ideal” signal in the mth voxel 
( )m TE  is represented as a sum of ( ; )x TE  across the volume (V) of the voxel:.  
                                                             ( ) ( ; )m mTE V x TE      ,                                    (1.19) 
where ( ; ) mx TE   is the averaged signal in the mth voxel. So the signal is first integrated 
across x in a single voxel and then the integral is substituted into Equation (1.17) with 
summations of voxels:  
          
~
0,( ; ) ( ) exp( 2 ) exp( ) sinc[( ) ]
2
x m x m m x mx x
m
mx mx mx
S k TE TE ik x i b TE i k k a
k g TE
   
  
        
 

 .   (1.20) 
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Inverse Fourier transform is applied to transform the k-space to an image domain. Thus, we have 
the expression for the signal at the nth voxel in the image domain corrected for the macroscopic 
magnetic-field inhomogeneity:
0, , ,
1
( ) { ( ) exp( ) sinc( ) exp[2 ( )]}n m m m x j x mx x x j x
m j
S TE TE i b TE i k a k a ik a n m
N
            . (1.21)  
In general, the overall signal in the nth voxel is determined by all the voxels in the image 
domain, including the “ideal” signal ( ( )m TE ), the accumulated phase due to the local 
macroscopic magnetic inhomogeneity ( mb , 0,m ), and the interactions between a certain voxel 
and other voxels (the sinc function part).  
To make this algorithm computationally feasible, we have another approximation that the signals 
from neighboring voxels evolve similarly over time in the absence of magnetic-field 
inhomogeneities so that, 
                                                          
| ( 0) |
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 .                                 (1.22)    
Under this approximation, we can extract ( )n TE  from the sum and reduce Equation (1.21) to, 
0, , ,
( ) ( ) ( )
1
( ) | (0) | exp( ) sinc( ) exp[2 ( )]
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n n n
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  
 
         
.                                                                                                                                               (1.23) 
where the F function ( )nF TE  is the voxel spread function describing the influence of 
macroscopic magnetic-field inhomogeneities at the nth voxel on the MRI image. The F-function 
can also be extended to 2D or 3D versions. To finish the computation projects in a reasonable 
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time, we used only neighboring voxels of the target voxel to compute ( )nF TE  instead of using all 
the voxels.  
1.2.4  Basic GEPCI Images (T1-weighted and R2*) 
With the signals in the image space ( )S TE , the voxel spread function ( )F TE  and a series of 
TEs, the standard R2* = 1/T2* map, and a T1-weighted (A0) image and frequency (Δf) map will 
be produced by fitting the following equation to experimental data on a voxel basis: 
                  *0 1 1( ) exp 2 ( ) 2 ( ( )S TE A R TE TE i f TE TE F TE           ,              (1.24)    
where TE is the gradient echo time, Δf is the frequency shift (dependent on tissue structure and 
also on the macroscopic magnetic field created mostly by tissue/air interfaces),  and where the 
function F(TE) describes the effects of macroscopic magnetic-field inhomogeneities (8). We use 
a voxel spread function (VSF) method (3) to calculate F(TE). 
Derived contrast images can also be constructed by using the same acquisition data according to 
(6). But they are not used in the current projects. 
 
1.3  Quantitative Blood-oxygen-level Dependent (BOLD) 
Imaging 
1.3.1  Blood-oxygen-level Dependent (BOLD) Effect 
R2* is a good quantitative measurement for evaluating microstructural tissue properties. 
However, except for the effect of the macroscopic magnetic-field inhomogeneity, there are more 
complicated and subtle susceptibility effects in the tissue-water environment. Unlike the 
macroscopic effect that biases the data, these susceptibility effects may provide interesting 
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information about the tissue on the cellular level. One of the most important susceptibility effects 
on the MRI signal is the blood-oxygen-level dependent (BOLD) effect discovered by Ogawa in 
1990 (9). The paramagnetic deoxyhemoglobin in blood vessels causes additional FID signal 
decay. Hemoglobin (Hb or Hgb) is a type of protein in red blood cells that contains iron and 
transports oxygen. When it carries oxygen from respiratory organs, it becomes diamagnetic 
oxyhemoglobin, the susceptibility of which is about -9 ppm, similar to that of water molecules in 
the soft tissue. When it releases the oxygen to provide energy and collects the resultant carbon 
dioxide back into the respiratory organs, it becomes paramagnetic deoxyhemoglobin with a 
susceptibility of about 0.15 ppm. The difference of the magnetic susceptibility distorts the local 
magnetic field and generates the BOLD contrast.   
One of the most important applications of the BOLD effect focuses on temporal changes in the 
MR signal during changes in brain activity, which is also known as function MRI (fMRI). 
Furthermore, the quantitation of the BOLD signal can provide information about the 
concentration of deoxyhemoglobin, which depends primarily on the oxygen extraction fraction 
(OEF) and the deoxygenated cerebral-blood volume (dCBV). This allows the BOLD contrast to 
be useful in understanding brain activities. However, the only clinically accepted OEF 
measurement relies on PET techniques (10), which are limited in human study and clinical 
practice due to their low spatial resolution and exposure to radiation.  
A quantitative MRI-based approach has been developed to analytically describe the MRI signal 
in the presence of a blood vessel network in the static dephasing regime (11). At first, this 
approach was developed to evaluate the NMR signal in the presence of magnetic inclusions, such 
as a blood vessel network, bone marrow, and a ferrite contrast agent. There are some common 
behaviors for all the systems. If the echo time TE is less than a characteristic time tc for a given 
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system, the signal decays exponentially with an argument which depends nonlinearly on TE. 
When TE is greater than tc, the signal follows a simple exponential decay and the relaxation rate 
does not depend on the echo time. 
This approach was used to separate tissue-specific R2t* and BOLD-related contributions from 
the total R2* relaxation (5, 12). The results for OEF, dCBV, and the concentration of 
deoxyhemoglobin in the gray matter can also be robustly calculated using this approach. The 
mean values of OEF and dCBV are 47% and 4.6%, respectively, which is in reasonable 
agreement with the literature (5). 
Several studies have been published to validate different aspects of this approach. Specifically, 
we have developed a theoretical model of the BOLD effect (11), validated it in phantom studies 
(8), conducted detailed measurements of blood magnetic susceptibility (13), validated the BOLD 
model in vivo using a rat model (14), and provided an analysis of systematic errors due to 
diffusion effects (15) and errors due to noise in the data (12, 16) 
1.3.2  qBOLD Model for Magnetic Inclusions in the Static Dephasing Regime 
Notice that this approach was developed on the assumption of a static dephasing regime in which 
diffusion may be ignored (11). In general, the diffusion phenomena would average out the phases 
of different nuclei. If NMR signal decay caused by magnetic moment dephasing occurs faster 
than diffusion—which means that the signal would decay before the diffusion averages the 
dephasing—then we are in the so-called static dephasing regime. If the water-diffusion 
coefficient D=1 µm2/ms and the transverse size of blood vessel is ~10 µm, it takes 100 ms to 
diffuse around a blood vessel. We can treat water molecules as static in the scan time (<40 ms). 
That is a mesoscopic scale. On the microscopic scale, a transverse size of a molecule may be 
~10A, so the water molecule would diffuse around and average the phase out before the signal is 
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measured. Thus, the diffusion needs to be considered, and we can treat the medium (water 
molecules, other small molecules) as a whole. 
1.3.3 qBOLD Model for the Blood Vessel Network 
Another major assumption is to model blood vessels as a set of cylinders with infinite length and 
arbitrary radiuses that are randomly distributed in the medium. The signal behavior in the 
presence of BOLD effect is then shown in ( )BOLDF TE  (11): 
                                                    ( ) exp[ ( )]BOLD sF TE f TE      .                                    (1.25)        
In practice, instead of the original function (11), we use a recently proposed expression (5), 
                                  
1
( ) 1 ( ) ( )
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BOLD s sF TE f TE f TE
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  
 
       
 
 ,                  (1.26)     
that better accounts for the presence of large vessels in the voxel than traditional exponential 
function (11).   is the deoxygenated cerebral-blood volume fraction (dCBV), and   is the 
characteristic frequency determined by the susceptibility difference between deoxygenated blood 
and surrounding tissue (11):   
                                                  0 0
4
(1 )
3
B Hct Y           .                               (1.27)    
In this equation, 0 0.27x ppm   (13) is the susceptibility difference between fully oxygenated 
and fully deoxygenated blood, Y is the blood oxygenation level (with Y=0 being fully 
deoxygenated), Hct is the blood hematocrit, and γ is the gyromagnetic ratio. Function sf  
describes the signal decay caused by the presence of the blood vessel network, which was 
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defined in (11). Herein we use a mathematical expression in terms of a generalized 
hypergeometric function 
1 2F  (17):  
                                      21 2
1 3 5 9
( ) ; , ; ( ) 1
2 4 4 16
sf TE F TE 
    
         
    
 .                   (1.28)    
This function has an interesting behavior. The function is nonlinear when 1TE    and linear 
when 1TE   , as is shown in Figure 1.3. 
 
 
 
 
 
 
 
Figure 1.3 The non-linearity of function ( )sf TE   versus TE  when 1TE   . The dots 
are values at the time of echos (t = TEn) assuming Y = 60%.  
 
Oxygen extraction fraction (OEF) is calculated as follows (18):  
                                                   
1
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
 
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 
.                     (1.29)                                  
The concentration of deoxyhemoglobin per unit tissue volume is calculated as follows (18): 
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,                                  (1.30)                                  
where Hbn  is the total intracellular Hb concentration equal to 
65.5 10 /mol mL  (18). Since Hct 
was not measured in GEPCI experiments, we will report only relative regional OEF ( relOEF ) 
values. 
                                                                   /rel meanOEF                                     (1.31) 
 
1.4  Summary 
In summary, my dissertation primarily uses the following two models: 
            
 *0 1 1
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             
,    (1.32)  
where TE is the gradient echo time, R2t*=1/T2t* is the tissue transverse relaxation rate constant 
(which describes GRE signal decay in the absence of the BOLD effect), Δf is the frequency shift 
(which depends on tissue structure and on the macroscopic magnetic field, which is created 
mostly by tissue/air interfaces), function ( )BOLDF TE  describes GRE signal decay due to the 
presence of a blood vessel network with deoxygenated blood (veins and the part of capillaries 
adjacent to veins), and function F(TE) describes the effects of macroscopic magnetic-field 
inhomogeneities. 
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By fitting the equation to the real and imaginary parts of the complex signal via a nonlinear 
regression algorithm, we are able to find the six parameters A0, R2*, R2t*, Δf,  , and   for 
each voxel in the brain. Based on the fitting results, we can calculate BOLD-related 
measurements, including OEF, dCBV, Cdeoxy, and 2R     . Examples of transverse MRI 
images are shown below in Figure [4]. 
Figure 1.4 Example of transverse GEPCI images computed from the models.  
 
The end of this chapter discusses these similar terms: R2*, R2, and R2t*. Note that, 
conventionally, in a gradient echo experiment, the total R2* relaxation rate constant is 
considered a sum of two components: the R2 relaxation rate constant, which represents the part 
of MR signal decay that cannot be reversed by a refocusing 180° RF pulse; and the 2R   
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relaxation rate constant, which represents the part of the signal decay that can be reversed by a 
refocusing 180° RF pulse: *2 2 2R R R   . Because GEPCI is based on a gradient echo 
sequence—although R2t* excludes the BOLD effect due to the blood vessel network—R2t* still 
includes the reversible component due to the magnetic susceptibility effects that result from the 
presence of different cellular components. This is the major difference between R2 and R2t*. 
Furthermore, R2 is usually used to represent the spin-spin interactions in a single compartment 
model where protons locate in a homogenous environment. However, due to the complicated 
biological environment, protons may locate in multiple compartments: e.g., protons in myelin 
layers, protons in axons, and protons in CSF. As a result, the interactions of protons with protons 
and protons with other biological molecules are not homogenous in the multiple compartment 
environment. In this circumstance, it is confusing to use R2 to represent all these spin-spin 
interactions, so this is considered the irreversible part of R2t*. All in all, although R2t* excludes 
the BOLD effect due to the blood vessel network, it still includes both an irreversible component 
due to spin-spin interactions (e.g., protons with protons and protons with other molecules) and a 
reversible component due to the susceptibility effects of biological components.  
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Chapter 2: Introduction to Normal Aging 
and Alzheimer’s Disease 
 
Alzheimer’s disease (AD) affected approximately 48 million people worldwide in 2015. Its 
devastating consequences have stimulated an intense search for AD prevention and treatment. 
Although normal aging and Alzheimer’s disease can cause similar cognitive deficits and clinical 
symptoms (e.g., memory loss), the underlying pathological changes are quite different. For 
decades, it has been commonly believed that normal aging causes significant neuron death in the 
neocortex and hippocampus. However, modern quantitative studies suggest that neuron number 
is preserved in normal aging, so neuron death is unlikely to account for the age-related 
impairment of neocortical and hippocampal functions. With significant brain atrophy and 
neocortical thinning, one can hypothesize that the neuronal density increases with increasing age, 
which is also supported by the literature. In contrast, there is considerable evidence for 
significant neuron loss in the hippocampal area in Alzheimer’s disease. Previous studies have 
also shown that neuronal damage is caused by neurotoxic pathological changes such as amyloid 
plaques and tau tangles. Therefore, it is necessary to review the qualitative and quantitative 
pathological changes of normal aging and Alzheimer’s disease with respect to neuron loss. 
Currently, radiotracers and positron emission tomography (PET) imaging are widely used to 
detect amyloid deposition and tau tangles in vivo. But there is also a potential for the GEPCI 
approach to the in vivo detection of these microstructural changes that avoids the disadvantages 
of PET imaging.  
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2.1 Normal Aging 
2.1.1  Non-significant Age-related Neuron Loss 
Although it is well known that normal aging can cause functional cognitive impairments, the 
neurobiological effects of normal aging (i.e., changes in the cellular content and organizations, 
including cerebral cortical thinning and atrophy) on functional and structural declines are still not 
well understood (19). A conventionally accepted idea dating back to the 1950s is that significant 
neuron death is found both in aged humans without AD and in nonhuman primates and rodents 
(20, 21). Although the percentage of neuron loss varies in these two studies, they both suggest 
that most neocortical regions and certain hippocampal subfields lose neurons by 25% to 50% 
with age. For example, Brody et al. (20) examined 20 brains of individuals between the ages of 
newborn to 95 years. They report that the cell number decreased with age in all cortical layers. 
The greatest decrease in cell number with increasing age occurred in the superior temporal gyrus 
followed by the precentral gyrus and then the area striata. However, the data may be confounded 
by species and strain differences, tissue processing, and sampling procedure. 
Application of stereological procedures to count the neurons of several species, including 
humans, yielded the surprising result that the number of neurons does not significantly change 
due to normal aging in the cortex and hippocampus (19). Consider a few studies that support this 
surprising result. Terry et al. (22) studied 51 brains from clinically and neuropathologically 
normal individuals ranging in age from 24 to 100 years. They report that the total neuron 
populations in the mid-frontal, superior temporal, and inferior parietal sections did not decline 
significantly with age. Furthermore, the total neuron counts in the young group did not differ 
significantly from those in the old group in the midfrontal cortex or the superior temporal cortex. 
Only in the inferior parietal area is the difference significant, but the p value is 0.05 at the cut-off 
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of significance level.  Haug and Eggers (23) examined 60 brains and report that the brain volume 
of frontal cortex significantly decreased but that loss of neurons cannot be found. As a result, the 
neuronal density increased in the frontal cortex. Furthermore, the size of neurons and the number 
of synapses decrease with age. Pakkenberg and Gundersen (24) examined 94 brains from a 
Danish population and report that the average numbers of neocortical neurons are 19 billion in 
female brains and 23 billion in male brains: a 16% gender difference. A rather small decline 
(approximately 10%) of neocortical neurons were found over the life span from 20 to 90 years in 
the human neocortex. However, they warn that, due to the experimental design, this small 
decline with age should not be considered strong evidence for biologically significant age-related 
neuron loss. Pakkenberg et al. examined the same 94 brain samples in 2003 (25) and report that 
the number of glial cells in six elderly individuals with a mean age of 89.2 years was not 
significantly different from that of six young individuals with a mean age of 26.2 years. 
Furthermore, the total myelinated fiber length varies from 150,000 to 180,000 km in young 
individuals and shows a large reduction with age. Freeman et al. (26) examined the cerebral 
cortex of 27 normal individuals ranging in age from 56 to 103 years. They found that the frontal 
and temporal neocortical regions exhibited clear evidence of cortical thinning with age but that 
total neuronal numbers in the frontal and temporal neocortical regions remained relatively 
constant over a 50-year age range. As a result, frontal and temporal cortical neuronal density 
showed a small but insignificant increase with increasing age. Freeman et al. also discuss what 
leads to cortical thinning. The data suggest that loss of neuronal and dendritic architecture, rather 
than loss of neurons, underlies neocortical volume loss and cortical thinning with increasing age 
in the absence of AD.  
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Based on the findings in literature, we can see neuron loss is not significant due to normal aging.  
In addition to neurons, the number of other CNS cells such as glial cells did not show significant 
differences between elderly individuals with a mean age of 89 years and young individuals with 
a mean age of 26 years (25). Furthermore, the glia/neuron ratio of 1.32 for females and 1.49 for 
males showed no statistically significant correlation with age over adult life (27). Thus, the 
published studies indicate that the total number of neurons and glial cells in the cortex remains 
relatively constant over normal adult life.  
2.1.2  Age-related Brain Atrophy and Cortical Thinning 
Cerebral volume loss and cortical thinning has been observed in various structural MRI studies 
associated with normal aging. A few studies are cited to support this observation. Scahill et al. 
(28) scanned 39 healthy control subjects ranging in age from 31 to 84 years. They find a 
significant decrease in cross-sectional whole brain, temporal lobe, and hippocampal volumes, 
and a significant increase in ventricular volume with age. Fotenos et al (29) also used structural 
MRI to scan 370 adults ranging in age of 18 to 97 years. 192 participants were non-demented, 
while the rest (98 participants) exhibited very mild to mild dementia of the Alzheimer type. They 
find that both cortical and white-matter volume decrease with age; gray matter volume declines 
in a linear fashion from early adulthood, whereas white matter volume loss appears to start later 
in life and does not follow a linear pattern. The onset of dementia is associated with an 
accelerated atrophy rate.  
Thinning of the cerebral cortex over age has also be found in many studies. A few studies are 
cited here to support this statement. Salat et al. (30) measured the cortical thickness in 106 non-
demented participants ranging in age from 18 to 93 years by using a T1-weighted MRI. They 
find that the global thickness significantly declines with increasing age. In regional measures, 
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significant thinning was found in the occipital lobe, the pre/post central gyrus, and the inferior 
lateral prefrontal cortex. Temporal lobe thinning is relatively less significant compared to that 
observed in other cortical areas. Similarly, our study (Chapter 3) (12) also shows that cortical 
thickness significantly decreases with age in most of the cortical regions segmented in 
FreeSurfer. The thinning rate varies across cortical regions of the brain. The 20 participants in 
this study were healthy controls ranging in age from 22 to 74 years.  
2.1.3  Neuronal Density may Increase with Age 
The unchanged number of neurons and the decreasing cortical volume imply increasing neuronal 
density with increasing age in the cortex, which is also supported by the results of Haug and 
Eggers (23, 31). They performed morphometric analysis of neurons on human brains and 
measured five Brodmann cortical areas. These areas include, (i) area 6 in the frontal lobe, also 
designated the supplementary motor area; (ii) area 11 in the orbital part of the frontal lobe, which 
is linked to psychosocial functions; (iii) area 7 in the parietal lobe, which is related to sensory 
and speech analysis; (iv) area 17 or the visual cortex in the occipital lobe; and (v) area 20 at the 
basis of the temporal lobe. The measurements are based on at least 50 brains in each area, except 
for area 20, for which the measurements of only 20 brains are provided. They find that the 
neuron density increases significantly with age in areas 6 and 11 in the frontal lobe (p = 0.01) 
and in area 17 in the occipital lobe (p = 0.001), while area 7 in the parietal lobe and area 20 in the 
inferior temporal gyrus show non-significant but increasing tendencies. They also confirm that 
the total number of neurons in the human cerebral cortex does not change during normal aging. 
This result may not be representative of brain regions other than the cortex. 
As mentioned above, Freeman et al (26) also find that frontal and temporal cortical neuronal 
density shows a small increase with increasing age. Although few studies directly measure 
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neuronal density over age, the unchanged number of neurons and cortical thinning with age are 
widely supported by previous studies, which is a strong indications of increased neuronal 
density. 
2.1.4  Age-related Dendritic and Synaptic Loss 
But if loss of neurons is not significant in normal aging, what leads to cortical thinning and 
volume loss? A more recent point of view is that relatively subtle alterations in synaptic 
connectivity, dendritic spine density, and neural plasticity (32-35) are associated with age–
related cognitive dysfunctions.  A significant reduction in the  dendritic arbors of pyramidal 
neurons located in the prefrontal, superior temporal, and precentral cortices, and changes in 
dendritic spine size, shape, and density across the neocortex in humans and animals are discussed 
by Dickstein (33). Hof and Morrison (34) argue that, while neuron death predominates in 
Alzheimer’s disease, age-related cognitive impairment is probably mediated by changes in 
synaptic communication rather than by neuron death.  Fjell et al. (32) also argue that regions 
with a high degree of life-long plasticity are more affected by normal aging effects. Freeman et 
al. (26) argue that previous studies suggest an age-related decrease in neuronal size (13) and a 
loss of presynaptic terminals (28). A loss of complexity of dendritic arborizations has also been 
described in Golgi studies of “normal” aging. The reported observation of volume loss in the 
white matter also suggests that some of the decrease in cortical thickness could be attributed to 
loss of ascending projections in the cortex. Together, these data suggest that loss of neuropil (i.e., 
neuronal structural complexity) might contribute to the dramatic thinning that occurs with 
increasing age. 
In summary, much evidence shows that neuron loss is not significant over the normal aging 
process, while cerebral atrophy and thinning are significant. Thus, neuronal density should 
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significantly increase with age. However, most of the studies cited that are related to neuronal 
structure were conducted on non-human primates or other animals or on post-mortem human 
tissues. Hence, it is essential to study the age-related cellular and functional alterations 
quantitatively in vivo and to establish a baseline for distinguishing normal aging from 
pathological effects. 
 
2.2 Alzheimer’s Disease 
2.2.1  A Staging Model of Alzheimer’s Disease 
Over the past two to three decades, a staging model of Alzheimer’s disease (AD) has been 
developed. Both AD pathological processes and clinical decline progress gradually. Pathological 
changes begin to develop decades before the earliest clinical symptoms occur. Dementia occurs 
at the last stage of many years of accumulation of these pathological changes. At present, the 
clinical diagnosis of AD requires the presence of dementia. 
The clinical disease stages of AD have been divided into three stages (36). The first is referred to 
as a pre-clinical stage in which individuals are cognitively normal but have AD pathological 
changes. Notice that some of these individuals die without ever showing AD clinical symptoms. 
The hypothesis is that an asymptomatic individual with AD-related pathological changes would 
ultimately have become symptomatic if he or she lived long enough. The second is commonly 
referred to as mild cognitive impairment (MCI), in which the earliest cognitive symptoms 
(typically deficits in episodic memory) occur but do not meet the criteria for dementia. The 
severity of cognitive impairment in the MCI stage varies from the earliest appearance of memory 
loss to more widespread dysfunction in other cognitive domains. The final phase in the evolution 
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of AD is dementia, in which impairments in multiple domains are severe enough to produce 
cognitive deficits.  
Dementia is the clinically observable result of the cumulative burden of AD pathological 
changes in the brain. A clinical diagnosis of dementia indicates that the patient has a disorder 
that precludes independent living and is on an inevitable course toward complete loss of 
independence. Most elderly patients with dementia have multiple pathological changes 
underlying their dementia. AD is the most common pathological substrate, which is referred to as 
dementia of the Alzheimer type (DAT).  
To date, all disease-modifying experimental therapies for AD have failed to demonstrate a 
clinical benefit in individuals with symptomatic AD (37, 38), possibly because the drugs were 
administered too late in the course of the disease, which begins 15-20 years prior to the onset of 
clinical symptoms (36, 39-45). As a result, the preclinical stage is an important time window for 
therapeutic intervention. Hence, one of the important directions in AD therapy is to develop 
widely accessible neuroimaging techniques that can detect AD brain pathology in the preclinical 
stages. Many biomarkers have been developed to detect pathological changes in the preclinical 
stage and to identify individuals who are destined to develop AD in the early disease course. 
Herein, several hallmark AD pathological changes and widely used biomarkers are introduced 
briefly. 
2.2.2  Amyloid Deposition 
One of the prevailing hypotheses of AD is the amyloid cascade hypothesis (36, 39, 41, 42), 
which suggests that abnormal accumulation of (Aβ) in the neocortex is one of the earliest 
pathological markers of AD. Aβ deposition is actually the product of a larger transmembrane 
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protein: the amyloid precursor protein (APP) (46). The abnormal metabolism of APP leads to 
excess production or reduced clearance of Aβ in the cortex.   
Both CSF Aβ42 and radiotracers of amyloid PET imaging are biomarkers of Aβ deposition. Klunk 
et al. (47) report the first human study of a novel amyloid PET imaging tracer—Pittsburgh 
Compound-B (PiB)—in 16 patients with diagnosed mild AD and 9 controls. The retention of PiB 
measured by PET imaging (PiB PET) in vivo reveals a large amount of amyloid deposits in 
cerebral cortical areas of the AD brains, especially in the prefrontal cortex and precuneus (47, 
48). PiB retention was equivalent in both AD patients and controls in areas known to be 
relatively unaffected by amyloid deposition (such as subcortical white matter, pons, and 
cerebellum). Studies in three young (21 years) and six older healthy controls (69.5 ± 11 years) 
showed low PiB retention in cortical areas and no significant group differences between young 
and older controls. Later on, Ikonomovic et al. (49) examined patients who underwent PiB PET 
imaging before death and autopsy. They report a strong direct correlation between PiB retentions 
in vivo and region-matched quantitative measures of amyloid plaques of the AD subjects. They 
also find that PiB binds specifically to fibrillary Aβ and not to soluble Aβ or diffuse Aβ plaques. 
This study further supports the validity of PiB-PET imaging as a method for in vivo evaluation of 
Aβ plaque burden.  
Low concentrations of CSF Aβ42 correlate with both the clinical diagnosis of AD and with Aβ 
neuropathology at autopsy. An inverse relation has been reported between in vivo PiB amyloid 
imaging and CSF Aβ42 in AD patients who have undergone both tests (50). The evidence 
therefore strongly supports the hypothesis that both amyloid imaging and low CSF Aβ42 are valid 
biomarkers of brain Aβ-plaque load.  
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However, amyloid deposition has been shown to start while individuals are still cognitively 
normal. It is hypothesized that, after an early phase of fast accumulation, a plateau is reached by 
the time of cognitive decline (36). In the study by Villain et al. (51), 32 patients with AD, 49 
subjects with MCI, and 103 healthy controls underwent two PiB PET scans 18 months apart. 
They report no significant association between the PiB retention rate of change and the clinical 
status or disease progression. Amyloid accumulation seems to slow down at the latest stages of 
the process. 
2.2.3  Neurofibrillary Tau Tangles 
So amyloid deposition is not related to clinical symptoms as closely as another hallmark 
abnormal protein deposit: neurofibrillary tangles (NFTs) formed by hyperphosphorylated tau. 
Bennett et al. (52) examined 44 individuals with clinically diagnosed AD and 53 without 
dementia with a uniform structured clinical evaluation for AD and cognitive testing about 8 
months prior to death, and brain autopsy at death. They report that, when a term for tau tangles is 
added to the multiple regression model with amyloid, the association of amyloid load with 
clinical disease or global cognitive tests is reduced by more than 60% and is no longer 
significant, whereas the association of tangles with clinical disease is essentially unchanged. 
Giannakopoulos et al. (53) examined 22 elderly cases with clinical dementia assessment 
(MMSE), stereological assessment of NFT, unaffected neurons, and total amyloid volume in the 
CA1 field of the hippocampus, entorhinal cortex, and Brodmann area 9 (frontal area). 
Multivariate analyses show that total NFT counts in the entorhinal cortex and area 9 as well as 
neuron numbers in the CA1 field are the best predictors of the MMSE score. The amyloid 
volume has no additional predictive value, in terms of clinicopathologic correlations, beyond its 
interaction with NFT. 
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However, the prior lack of imaging agents has limited studies of tau to postmortem examinations 
or measures that lack topographic information such as measurement of tau in CSF. A recent 
study by Brier et al. (54) reports PET imaging of tau and Aβ in a cohort of cognitively normal 
older adults and older adults with mild AD. They also discuss the fact that tau deposition in the 
temporal lobe more closely tracks dementia status and is a better predictor of cognitive 
performance than Aβ deposition in any region of the brain.  
2.2.4  Neuron Loss in the Hippocampal Area 
However, an autopsy study has confirmed that gross cerebral atrophy (indicating the loss of 
synapses and neurons), and not Aβ or NFT burden, is the most proximate pathological substrate 
of cognitive impairment in AD. For example, Savva et al. (55) assessed 456 brains from people 
69 to 103 years of age at death. They report that the associations between dementia and 
pathological changes (amyloid deposition and tau tangles) attenuate with increasing age. In 
contrast, atrophy of the hippocampus and the neocortex is strongly associated with dementia at 
all ages.  
Based on the above discussions, Aβ abnormalities precede tau abnormalities and NFTs precede 
cerebral atrophy. Additionally, patterns of gray matter loss are associated with NFT pathology at 
Braak stages V and VI (56). 83 subjects with Braak stage III through VI underwent ante-mortem 
and post-mortem AD staging. The Braak stage V and VI groups showed a pattern of gray-matter 
loss affecting the medial temporal lobes (MTL), including the hippocampus, the entorhinal 
cortex, and the adjacent parahippocampal gyrus, which is vulnerable to NFTs. Subjects with a 
high tau burden showed a pattern of gray-matter loss affecting the hippocampus, 
parahippocampal gyrus, and lateral temporal lobes compared with subjects with a low tau 
burden.  
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Indeed, the medial temporal lobe is an essential area related to human memory and to AD.  
Reduction of volume and loss of cells in the entorhinal cortex and hippocampus have been 
extensively reported in participants with mild cognitive impairment (MCI) and AD (57-61). For 
example, Price et al. (59) examined the neuron number and volume in the entorhinal cortex and 
CA1 field of the hippocampus from 4 groups of participants, including 13 non-demented cases 
with healthy brains, 4 cases with preclinical AD, 8 cases with very mild symptomatic AD, and 4 
cases with severe AD. They report no significant decrease in neuron number or volume with age 
in the healthy non-demented group and little or none in the healthy and preclinical AD groups. 
They report substantial decreases in neuron number and volume in the very mild AD group. 
Greater damage was observed in CA1 in the severe AD group. The results indicate that 
symptomatic AD begins only when neuron loss occurs in the hippocampal area, which is 
consistent with the study by West et al (62). 
The posterior parahippocampal gyrus draws relatively less attention, but several studies have 
reported its atrophy due to aging (63) and AD (64). The presence of neurofibrillary tangles 
(NFTs) and neuronal loss in the parahippocampal gyrus—previously reported by Thangavel et al 
(65)—can also affect R2* measurements. However, their participants were assessed at death 
after nearly a decade of dementia. In addition, tissue damage in the parahippocampal gyrus was 
smaller than that in the hippocampus (66).  
2.2.5  Clinical Dementia Rating (CDR) 
The above sections introduce hallmark AD pathological features. This section introduces a 
clinical evaluation for identifying cognitive impairment. This evaluation, referred to as clinical 
dementia rating (CDR), has been developed by Washington University. The CDR is a 5-point 
scale used to characterize six domains of cognitive and functional performance applicable to 
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Alzheimer disease and related dementias: memory, orientation, judgement & problem solving, 
community affairs, home & hobbies, and personal care. The necessary information to make each 
rating is obtained through a semi-structured interview of the patient and a reliable informant or 
collateral source (e.g., a family member). The score is useful for characterizing and tracking a 
patient’s level of impairment/dementia: 
0 = Normal 
0.5 = Very Mild Dementia 
1 = Mild Dementia 
2 = Moderate Dementia 
3 = Severe Dementia 
The scoring rule is to use all of the information available and to make the best judgement. Score 
each category (M, O, JPS, CA, HH, PC) as independently as possible. Mark in only one box for 
each category, rating impairment as a decline from the person’s usual level due to cognitive loss 
alone, not impairment due to other factors, such as physical handicap or depression. Occasionally 
the evidence is ambiguous and the clinician’s best judgment is that a category could be rated in 
either one of two adjacent boxes, such as mild (CDR=1) or moderate (CDR=2) impairment. In 
this situation, the standard procedure is to check the box of greater impairment. The derivation of 
the global CDR from the scores in each of the six categories is described in detail by Morris (67).  
2.3 MRI Application in Microstructural Changes 
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As mentioned above, PET imaging is widely used to measure the retentions of biomarkers of 
amyloid and tau deposition in AD studies. But MRI is widely available worldwide, is non-
invasive ,and does not require radiation exposure. For both normal aging and AD, a structural 
MRI can provide accurate volume measurements as post-mortem measurements. For example, 
Bobinski et al. (68) examined 11 AD cases and 4 healthy controls and measured the post-mortem 
volumes of the hippocampal subdivisions by using MRI and histological sections. They report 
strong correlations between these two measurements, which indicate that an accurate volumetric 
measurement of the hippocampus can be obtained via MRI. However, atrophy occurs at a later 
stage of the AD process, so structural MRI cannot effectively give an early diagnosis for the 
preclinical stage. Furthermore, the volumetric measurements lack biological information, so a 
quantitative MRI technique is needed to identify early AD pathological changes and to provide 
biological information at a microstructural level.  
This is possible because all of the AD pathological processes that contribute to the pathogenesis 
of Alzheimer’s disease at the cellular level lead to changes in the environment of local tissue 
water molecules – a major source of MRI signal. Hence, in addition to measuring brain atrophy 
by using volumetric MRI, a properly designed MRI technique can enable local water molecules 
to report on regional biological tissue properties at the cellular level.  
The GEPCI approach could be a potential candidate for this motivation. The GEPCI approach 
has been used to identify brain tissue damage in multiple sclerosis (2, 4, 69-72) and psychiatric 
diseases (73). R2* values have been found to be significantly lower in patients with multiple 
sclerosis (MS) than in healthy participants (2, 4, 69-72). Significant correlations between age-
adjusted R2* measurements and clinical scores of MS have also been reported for cortical 
regions (71). Significant group effects based on GEPCI measurements have been observed in the 
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superior temporal cortex and in the thalamus in participants with schizophrenia and bipolar 
disorder Because GEPCI metrics (R2* and R2t*) are sensitive to the tissue-water environment in 
the human brain, the measurements can be very hard to interpret. As a result, GEPCI is first 
applied to study healthy controls with normal aging, (i) to establish an age-related baseline, and 
(ii) to gain a better understanding of the biological interpretation of GEPCI metrics (12). GEPCI 
is then utilized to detect the pathological changes of the preclinical and the early Alzheimer 
disease in vivo (74).  
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Chapter 3: On the Relationship between 
Cellular and Hemodynamic Properties of  the 
Human Brain Cortex Throughout Adult 
Lifespan 
 
3.1 Introduction 
Establishing baseline MRI biomarkers for normal brain aging is significant and valuable for 
separating normal aging effects from neurological diseases. In this study, for the first time we 
have simultaneously measured a variety of tissue specific GEPCI metrics of healthy adults (ages 
22 to 74 years), such as T1-wegihted, R2*, R2t*, OEF, dCBV and Cdeoxy. GEPCI metrics are 
utilized to establish quantitative in vivo biomarkers characterizing the age-related evolution of 
tissue structural and functional properties of adults. Two main goals of this study are: (i) to 
investigate the age-related changes of GEPCI metrics so a baseline for normal aging can be 
established; (ii) based on GEPCI age-related results and what we know about the pathology of 
normal aging from the literature (reviewed in Chapter 2), find out a proper biological 
interpretation for GEPCI metrics, especially R2* and R2t*. Both the age-related baseline and the 
biological interpretation of GEPCI metrics are essential for us to investigate diseases in the 
future. 
The data (20 healthy subjects) show that in most cortical regions R2t* increases with age while 
tissue hemodynamic parameters, i.e., relative oxygen extraction fraction (OEFrel), deoxygenated 
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cerebral blood volume (dCBV) and tissue concentration of deoxyhemoglobin (Cdeoxy) remain 
practically constant. R2t* describes the part of the signal decay resulting from water molecule 
interactions with cellular and extracellular components of biological tissues.  By comparing our 
results with the literature data, we hypothesize that in the normal brain it can serve as a 
biomarker of the cortical “cellular packing density” – a parameter mostly proportional to the 
number of neurons and glia cells in the unit tissue volume – and can potentially identify tissue 
alterations (see further comments in the Discussion section). We also use this hypothesis to 
explain the relationships between R2t* and the functional data (e.g., OEF). Specifically, thicker 
cortical regions have lower R2t* and these regions have lower OEF. 
The baseline GEPCI-based biomarkers obtained herein could also serve to help distinguish age-
related changes in brain cellular and hemodynamic properties from changes which occur due to 
neurodegenerative diseases, e.g., (71). 
 
3.2 Methods 
3.2.1  Participants 
This study was approved by the Institutional Review Board of Washington University School of 
Medicine. Twenty participants aging from 22 to 74, including 7 male (ages: 22, 26, 29, 35, 37, 
42, 65) and 13 female (ages: 23, 28, 33, 42, 45, 46, 50, 52, 56, 57, 61, 61, 74), were recruited in 
this study. None of the participants had any history of neurological diseases. All participants 
provided informed consent.  
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3.2.2  Data Acquisition 
All subjects were scanned in a 3T Trio MRI scanner (Siemens, Erlangen, Germany). A 3D multi 
gradient echo sequence was used to obtain the data. Sequence parameters were: resolution 1×1×2 
mm3 (read, phase, slab), FOV 256 mm×192 mm, repetition time TR = 50ms, flip angle 30°, 10 
gradient echoes with first gradient echo time TE1 = 4 ms, echo spacing ∆TE = 4ms. Additional 
phase stabilization echo (the navigator data) was collected for each line in k-space to correct for 
image artifacts due to the physiological fluctuations (4). The total acquisition time of GEPCI is 
11 mins 30s. Field inhomogeneity effects were removed by using the voxel spread function 
(VSF) approach (3). Standard clinical Magnetization-Prepared Rapid Gradient Echo (MPRAGE) 
(75) images with TR/TI/TE = 2200/1100/3.37 ms and the resolution 0.9×0.9×1.5 mm3 were also 
collected for segmentation purposes. The total acquisition time of MPRAGE is 6 mins. After the 
data acquisition, the raw k-space data were read into MATLAB (The MathWorks, Inc.) for the 
post-processing.  
3.2.3  Data Analysis and Image Generation 
The image processing was finished in MATLAB (The MathWorks, Inc.) using models described 
in Chapter 1: 
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        (3.1)               
where TE is the gradient echo time, R2* is the global transverse relaxation rate constant, 
R2t*=1/T2t* is the tissue transverse relaxation rate constant in the absence of BOLD effect, Δf  
is the frequency shift (dependent on tissue structure and also macroscopic magnetic field created 
mostly by tissue/air interfaces), function ( )BOLDF TE  describes GRE signal decay due to the 
presence of blood vessel network with deoxygenated blood (veins and the part of capillaries 
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adjacent to veins), and function F(TE) describes the effects of macroscopic magnetic field 
inhomogeneities. 
As mentioned in Chapter 1, by fitting the equation to the real and imaginary parts of the complex 
signal using nonlinear regression algorithm, six parameters are computed: A0 (T1-weighted), 
R2*, R2t*, Δf,  and   for each voxel in the brain.  and   are computed from ( )BOLDF TE . 
Based on the fitting results, BOLD-related measurements are computed, including OEF, dCBV, 
and Cdeoxy. 
In this study, the relative regional OEF (OEFrel) is reported as: 
                                                                /rel meanOEF                                                    (3.2)                                                                                                        
where mean  is the mean across the cerebral cortex and  represents one single cortical region. 
3.2.4  Image Segmentation 
MPRAGE images were input into FreeSurfer (Laboratory for Computational Neuroimaging, 
Martinos Center for Biomedical Imaging) (76) to generate brain segmentations and calculate 
cortical thickness. 26 cortical regions of interest (ROI), covering frontal, temporal, parietal and 
occipital lobes, were chosen to characterize an individual participant’s cortex. The thalamus, 
caudate, putamen, pallidum, hippocampus and amygdala were chosen to study the subcortical 
regions.  
MPRAGE images were registered to GEPCI-T1-weighted images using FMRIB’s (Functional 
Magnetic Resonance Imaging of the Brain) Linear Image Registration Tool (77, 78) in FMRIB 
Software Library (FSL) and the transformation matrices of the registration were computed. 
Finally, these matrices were applied to the brain segmentations from FreeSurfer and transformed 
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them to the space of GEPCI-T1-weighted images. Since GEPCI –T1-weighted images are 
naturally co-registered with all GEPCI maps (R2*,R2t*, OEFrel, Cdeoxy, and dCBV), the 
segmentations were also naturally registered to all these maps.  
Even though the data were collected with rather high in-plane resolution – 1x1 mm2, they are 
still susceptible to the partial volume effect (edge values, outliers). To minimize it, a CSF mask 
generated from FSL is applied further removing CSF signals from FreeSurfer segmentations. 
Furthermore, in each of the FreeSurfer ROIs which usually contains thousands of voxels, the 
median of the corresponding measurement distribution was computed because it is less sensitive 
to outliers. This procedure also minimizes the errors in the model parameters estimates discussed 
in 3.2.6 Error analysis.    
3.2.5  Image Segmentation 
The correlations and linear regressions were established using the LinearModel class in 
MATLAB (The MathWorks, Inc.). As mentioned above, for each GEPCI parameter, the median 
value was calculated across thousands of voxels within each Freesurfer ROI. As a result, an 
individual participant has 7 parameters (R2*, R2t*, OEFrel, dCBV, Cdeoxy, cortical thickness (Th), 
and SR2t*=R2t*×Th) and 26 median values from the cortical ROIs for each parameter. So for 
each parameter and each ROI, the following equation is used to calculate a correlation and linear 
regression between the parameter and age across 20 participants: 
                                              ( 40)ROI ROI ROIparameter a k age                             (3.3)    
Age 40 years was selected arbitrarily as the adult reference age for the convenient interpretation 
of the intercept ROIa . Then ROIa  represents the characteristic value of a parameter within a ROI 
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taking into account all 20 participants. ROIa  corresponds to an averaged 40-year old adult. There 
are 26 ROIa  and ROIk  for each parameter across the cortical ROIs. To visualize the distribution of 
the parameters across 26 cortical ROIs, ROIa  can be mapped onto the Freesurfer brain surface. 
ROIa  is used to investigate the relationship between parameters across 26 cortical ROIs. If the 
parameter doesn’t have a significant linear relationship with age, the characteristic value of the 
parameter within a ROI is just the average across all the participants. The p-values were 
calculated to evaluate each correlation and conventionally p < 0.05 is considered as a significant 
correlation. Multiple comparison analysis was not applied here because we only reported 
individual correlations instead of comparing them across different ROIs.  
3.2.6  Error Analysis 
The simulated data were generated to test the accuracy of the theoretical model, Equation (3.1), 
used in this study. As the frequency ( f ) has minimal effects on the fitting process, only the 
amplitude of the signals were used in this simulation. First, the true values of the parameters 
were assigned based on our typical results: R2t* = 17, OEF = 40%, and dCBV = 3%. Then the 
parameters were substituted into Equation (3.1) to generate the “true” signals over 10 TEs from 
4ms to 40ms. Second, a set of “real” signals over 10 TEs was generated by adding the random 
noise to the true signals. A typical SNR in GEPCI experiments is between 300 and 500 (for 
Hanning filtered data). In the simulated data, the noise corresponding to SNR equal to 400 is 
used. The random noise values were drawn from the standard normal distribution generated by a 
built-in function in MATLAB. In total, 500,000 sets of the simulated signals were generated in 
this way. Third, the same fitting routine was applied to each set of the simulated signals to 
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calculate the output parameters. Finally, the medians, means and standard deviations of each 
parameter were calculated. 
 
3.3 Results 
3.3.1  Age-related Changes in the Cerebral Cortex 
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Figure 3.1 Examples of the scatter plots of (a) R2*, (b) R2t*, (c) OEFrel (local-to-global ratios, 
Eq. [2]), (d) dCBV, (e) Cdeoxy, (f) cortical thickness (Th) and (g) SR2t* versus age are shown in 4 
selected cortical ROIs. Each plot represents the data from a single cortical region and each point 
in the plot represents a single participant. Male subjects are represented by blue points and 
female subjects by red points. For R2*, R2t* and cortical thickness, the solid lines are the 
regression curves and the p values evaluate the significance of the linear model. SR2t*, OEFrel, 
dCBV and Cdeoxy show no significant change with age and are represented by a constant model 
(the solid lines). The dashed lines in all plots represent the 95% confidence intervals. Number of 
asterisks or “stars” show significance level: p < 0.01 (**), p < 0.05 (*). The results of regression 
analysis from all other regions are listed in Table 3.1 and Table 3.2. 
 
The data (Figures 3.1 and 3.2, Tables 3.1 and 3.2) show that in most cortical regions R2* and 
R2t* increase with age, OEFrel, dCBV and Cdeoxy remain constant while cortical thickness, Th, 
decreases. In addition to parameters listed above, we have also introduced a parameter SR2t* 
that represents an integrated characteristic of R2t* under a unit square of the cortex and is 
computed as a product of the median R2t* and Th for each FreeSurfer region: SR2t*=R2t*×Th. 
The detailed role of this parameter will be addressed in the Discussion section.  
Figure 3.1a shows that R2* statistically significantly increased (p < 0.05) with age in the 
example cortical ROIs. Furthermore, 21 out of 26 regions listed in Table 3.1 demonstrated that 
R2* significant increase over age with varying rates (slopes). Although a few regions showed 
non-significant results, all slopes were positive demonstrating an increasing trend of R2* over 
age.  
Figure 3.1b shows that R2t* also significantly increased (p < 0.05) with age in the example 
ROIs. Furthermore, 15 out of 26 regions listed in Table 1 showed significant increase over age 
with varying rates (slopes). In general, p values for R2t* regression are higher than those for R2* 
regressions. As a result, a few regions with significant increases in R2* showed non-significant 
increases in R2t*. For example, in the insula cortex, R2* significantly increased with age (p = 
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0.020) while R2t* did not (p = 0.14). Again, all slopes were positive. So although some regions 
didn’t have significant results, there was always an increasing trend of R2t* over age. 
Figure 3.1c shows that the relative OEF (OEFrel, a local-to-global ratio, Equation (3.2)), showed 
no significant trend with age – the p values of the linear model were not significant (p > 0.05) in 
all cortical regions except the rostral-middle frontal (p= 0.013) and the lateral occipital (p= 
0.026). To describe this data, a constant model is used in all cortical regions. The mean values of 
OEFrel are shown in Figure 3.1 as solid lines with the 95% confidence intervals shown as dashed 
lines. The mean values and standard deviation were listed in Table 3.2. The mean values of 
OEFrel ranged from 0.6 to 1.5 across the selected 26 ROIs. The regions in occipital lobe, such as 
cuneus, lingual and lateral occipital, have comparatively higher OEFrel (Table 3.2).  
Results for dCBV (Figure 3.1d and Table 3.2) and Cdeoxy (Figure 3.1e and Table 3.2) showed 
similar properties as OEFrel. They have no statistically significant linear trend over age. As a 
result, a constant model was used for them. The mean values and standard deviation were listed 
in Table 3.2. 
Figure 3.1f shows that cortical thickness significantly decreased (p<0.05) with age in the 
example regions except in superior frontal (p=0.11). Furthermore, 17 out of 26 regions listed in 
Table 3.1 showed significant cortical thinning over age with varying rates (slopes, mm/year). But 
all slopes are negative, which indicate age-related thinning varied in different regions of the 
brain.   
Results for the integrated parameter SR2t* were analyzed using the same procedure as OEFrel 
and showed no significant linear relationships with age. They were presented using a constant 
model demonstrating no significant changes over the studied human lifespans for each ROI 
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except caudal anterior cingulate (Figure 3.1g). The mean and standard deviation were listed in 
Table 3.2. 
 
Table 3.1 
ROI  R2* R2 
 name slope intercept pvalue slope intercept pvalue 
banksst 0.029 18.6 0.020 0.028 16.5 0.021 
caudal-anterior cingulate 0.031 15.6 0.011 0.052 13.5 0.004 
caudal-middle-frontal 0.034 17.6 0.006 0.021 15.8 0.120 
cuneus 0.040 19.7 0.005 0.043 17.8 0.007 
fusiform 0.034 18.9 0.007 0.023 16.4 0.093 
inferior parietal 0.034 18.2 0.002 0.029 16.3 0.012 
isthmus cingulate 0.038 18.3 0.003 0.044 17.2 0.001 
lateral occipital 0.041 20.6 0.015 0.040 18.1 0.032 
lingual 0.048 19.9 0.005 0.051 18.3 0.009 
middle temporal 0.037 18.5 0.002 0.030 14.8 0.060 
parahippocampal 0.031 17.2 0.055 0.004 15.0 0.841 
paracentral 0.043 19.0 0.001 0.039 17.6 0.027 
parsopercularis 0.042 17.0 0.001 0.042 14.8 0.005 
parsorbitalis 0.024 18.9 0.106 0.006 15.1 0.699 
parstriangularis 0.033 17.6 0.010 0.019 15.0 0.392 
postcentral 0.030 18.3 0.005 0.032 16.2 0.017 
posterior cingulate 0.029 16.6 0.003 0.028 15.2 0.015 
precentral 0.037 18.4 0.003 0.032 16.5 0.020 
precuneus 0.033 18.0 0.004 0.034 16.4 0.003 
rostral-anterior cingulate 0.014 15.6 0.227 0.006 11.9 0.762 
rostral-middle-frontal  0.020 17.1 0.074 0.011 14.8 0.417 
superior frontal 0.027 16.6 0.008 0.027 14.7 0.021 
superior parietal 0.023 18.3 0.072 0.021 16.1 0.197 
superior temporal 0.038 17.6 0.002 0.017 14.4 0.275 
supramarginal 0.033 17.6 0.001 0.028 15.5 0.020 
insula 0.022 15.5 0.036 0.020 12.5 0.143 
 
Table 3.1 continues on the next page 
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Table 3.1 (continue) 
ROI  Thickness 
name  slope intercept pvalue 
banksst -0.0095 2.51 0.001 
caudal-anterior cingulate -0.0018 2.52 0.617 
caudal-middle-frontal -0.0052 2.49 0.020 
cuneus -0.0035 1.78 0.112 
fusiform -0.0064 2.72 0.002 
inferior parietal -0.0060 2.39 0.007 
isthmus cingulate -0.0030 2.36 0.347 
lateral occipital -0.0038 2.18 0.023 
lingual -0.0043 2.00 0.022 
middle temporal -0.0082 2.86 0.007 
parahippocampal -0.0081 2.69 0.036 
paracentral -0.0050 2.36 0.072 
parsopercularis -0.0081 2.51 0.001 
parsorbitalis -0.0039 2.62 0.228 
parstriangularis -0.0053 2.36 0.028 
postcentral -0.0046 2.03 0.014 
posterior cingulate -0.0055 2.45 0.016 
precentral -0.0064 2.51 0.021 
precuneus -0.0060 2.31 0.009 
rostral-anterior cingulate -0.0040 2.76 0.212 
rostral-middle-frontal  -0.0031 2.23 0.168 
superior frontal -0.0047 2.63 0.115 
superior parietal -0.0040 2.12 0.094 
superior temporal -0.0074 2.77 0.008 
supramarginal -0.0073 2.53 0.001 
insula -0.0051 3.02 0.002 
 
Table 3.1: The parameters of Equation 3.3 and p-values for R2*, R2t*, and cortical thickness in 
26 selected FreeSurfer ROIs across 20 healthy subjects. 
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Table 3.2 
ROI OEFrel dCBV(%) Cdeoxy ( µM) SR2t*(mm/s) 
 name mean std mean std mean std mean std 
banksst 1.14 0.30 3.23 1.22 18.2 6.0 41.0 3.2 
caudal-anterior cingulate 0.87 0.54 2.79 1.99 15.2 10.2 34.3 3.4 
caudal-middle-frontal 1.02 0.20 2.65 0.53 15.5 3.9 39.1 2.7 
cuneus 1.10 0.31 2.70 1.69 14.4 8.5 31.9 3.4 
fusiform 1.29 0.21 3.36 1.08 21.0 5.2 44.4 2.8 
inferior parietal 1.07 0.22 3.03 0.68 16.5 4.0 38.7 2.5 
isthmus cingulate 1.02 0.35 1.18 0.90 6.7 4.5 40.7 3.8 
lateral occipital 1.29 0.14 4.25 1.10 23.4 5.4 39.6 2.9 
lingual 1.43 0.42 1.88 1.41 10.5 6.5 36.6 2.8 
middle temporal 1.05 0.29 6.45 1.59 37.8 9.0 42.1 3.0 
parahippocampal 0.99 0.46 1.86 1.41 12.3 8.5 39.8 4.8 
paracentral 1.52 0.52 1.12 0.99 8.1 6.6 41.5 4.3 
parsopercularis 0.98 0.39 3.09 1.29 17.7 6.1 37.1 2.7 
parsorbitalis 1.13 0.49 6.12 1.98 36.2 9.3 39.5 3.4 
parstriangularis 0.87 0.36 4.48 2.29 25.1 11.2 35.2 3.9 
postcentral 1.21 0.18 2.43 0.88 15.1 5.7 32.9 2.7 
posterior cingulate 0.75 0.30 1.88 0.99 10.1 5.5 37.1 2.3 
precentral 1.21 0.17 2.21 0.69 13.7 4.7 41.3 3.4 
precuneus 0.89 0.33 2.44 0.89 13.0 5.0 37.7 2.8 
rostral-anterior cingulate 0.60 0.17 6.25 2.36 34.3 11.1 32.9 5.0 
rostral-middle-frontal  0.63 0.20 4.16 1.36 20.9 4.9 33.0 2.7 
superior frontal 0.75 0.17 2.74 0.62 15.5 4.3 38.5 3.2 
superior parietal 1.25 0.28 2.80 0.74 16.9 5.6 34.2 3.7 
superior temporal 0.72 0.22 5.17 1.33 29.1 6.7 39.5 3.8 
supramarginal 0.89 0.20 3.23 0.94 17.6 5.1 39.0 2.7 
insula 0.60 0.22 3.46 1.04 20.7 6.0 37.8 2.7 
 
Table 3.2: The mean values and standard deviations of the OEF, dCBV, Cdeoxy, and SR2t* in 26 
selected FreeSurfer ROIs across 20 healthy subject. 
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3.3.2  The Distribution of Parameters on the Brain Surfaces 
 
Figure 3.2 The distributions of all GEPCI-derived parameters are presented on the lateral and 
medial cortical surfaces of the left hemisphere, including R2* (s-1), R2t* (s-1),  OEFrel,  
dCBV(%), Cdeoxy (µM),  cortical thickness (Th) (mm), SR2t* (mm/s), and the regression slope (
ROIk from Equation (3.3)) of R2t*  vs. age (s
-1/year). Images for R2*, R2t*, and Th use the 
regional characteristic values ROIa  from Equation (3.3). Images for SR2t*, OEFrel, dCBV and 
Cdeoxy use the regional mean values averaged across all subjects (Table 3.1) because they don’t 
have a significant linear relationship with age. The surface of the cortex was generated by the 
FreeSurfer at the depth of 0.5 (the voxels in the center of gray matter were sampled). White 
matter, deep grey matter and ventricles were excluded.  
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The distributions of all the GEPCI-derived parameters is presented on the lateral and medial 
cortical surfaces of the left hemisphere in Figure 3.2. Images for R2*, R2t*, and Th use the 
regional characteristic values ROIa  from Equation 3.3. Images for SR2t*, OEFrel, dCBV and 
Cdeoxy use the regional mean values averaged across all subjects (Table 3.1) because they don’t 
have a significant linear relationship with age. The ventricles, white matter and deep gray matter 
are excluded. R2* and R2t* have a similar distributed network. Frontal lobe, inferior parietal, 
precuneus and posterior cingulate have relatively lower values than paracentral lobule, lateral 
occipital, cuneus and lingual. This distribution feature is consistent with the previously reported 
T2* mapping at 7 T resulting from the averaging of 14 subjects (79). 
3.3.3  Correlations between Structural and Hemodynamic Cortical Tissue 
Properties 
 
 
 
 
 
 
 
Figure 3.3 The correlation and linear regression of (a) R2t* versus cortical thickness; (b) R2t* 
versus OEFrel; Each point represents the characteristic value of each FreeSurfer ROIs. The 
regional characteristic values of R2t* and thickness correspond to ROIa  from Equation (3.3). 
Since OEFrel remains constant with age in the cortical regions, the characteristic values of OEFrel 
are just the mean values across the subjects in the corresponding regions. All the coefficients 
from the linear regressions are listed in Table 3.3 
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Table 3.3: The regression coefficients, p values and Pearson correlation coefficients for R2t* vs. 
Thickness and R2t* (s-1) vs. OEFrel. Data represent averages from 20 healthy subjects across 26 
selected FreeSurfer ROIs displayed in Figure 3.3. 
 
The regional characteristic values of R2t* and thickness correspond to ROIa  from Equation (3.3). 
Since OEFrel remains constant with age in the cortical regions, the characteristic values of OEFrel 
are just the mean values across the subjects in the corresponding regions. R2t* correlates 
negatively with the cortical thickness across 26 cortical ROIs (p < 0.05 and r = 0.71, Figure 
3.3a). This correlation indicates that the thinner cortex has a relatively higher R2t*. Furthermore, 
R2t* positively correlates with OEFrel across 26 cortical ROIs (p < 0.05 and r = 0.8, Figure 3.3b). 
The regions extracting more oxygen also have higher R2t*. Implications of all these correlations 
will be discussed in detail in the Discussion section. 
3.3.4  Age-related Changes of R2* in Subcortical Regions 
 
 
 
 
 
Table 3.4: The regression coefficients and p values of R2* vs. age in 6 subcortical ROIs.  Data 
represent results from 20 healthy subjects displayed in Figure 3.4. 
 
Table 3.3 
  slope  intercept p value r 
R2t* (s-1)  vs. Thickness (mm) -3.96 25.3 4.34E-05 0.71 
R2t* (s-1)  vs. OEF 5.09 10.5 6.94E-07 0.8 
Table 3.4 
ROI R2* (s-1) 
name slope  intercept p value 
caudate 0.094 21.4 0.0003 
putamen 0.209 24.0 0.0003 
pallidum 0.178 34.8 0.0004 
thalamus 0.013 21.0 0.1635 
hippocampus 0.024 16.9 0.0816 
amygdala 0.035 15.4 0.0341 
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Figure 3.4 The scatter plots and linear regressions of R2* versus age in subcortical ROIs. Each 
plot represents the data from a single subcortical region and each point in the plot represents the 
median value in the region from a single subject. Male subjects are represented by blue points 
and female subjects by red points. The solid lines are the regression curves and the dashed lines 
are the 95% confidence intervals. All the coefficients from the linear regressions are listed in 
Table 4. p < 0.001 ***, p < 0.01 **, p < 0.05 *.    
 
R2* significantly increases with age in basal ganglia (caudate, putamen and pallidum), and 
amygdala. Thalamus and hippocampus show less significant age-related changes. Notice that 
R2* in the basal ganglia is substantially larger than R2* in the cortex. This is because basal 
ganglia is rich of iron deposition, which is paramagnetic and cause R2* to increase significantly. 
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3.2.5  Error Analysis 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 The histograms of the simulated data for R2t*, OEF, dCBV and Cdeoxy are shown 
with true values (black) and median values (red). The black and red lines overlap in the 
histogram of OEF. Note that the peak in OEF histogram at the lower boundary is due to the 
restriction set in the fitting routine (OEF > 10%). 
 
 
Table 3.5: The true values, medians, means and standard deviations of all the parameters in the 
simulations are listed here. The medians more accurately represent true values than the means for 
all the parameters. 
       Table 3.5    
 
      A0 R2t* (s
-1)     OEF (%) dCBV (%)  Cdeoxy ( µM) 
true values 100.00 17.00 40.00 3.00 22.44 
median 99.94 16.91 40.01 3.43 24.63 
mean 99.85 16.44 40.80 4.12 27.04 
standard deviation 0.75 2.06 17.32 2.60 10.73 
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The results are listed in Table 3.5. The histograms of the output parameters, and the 
corresponding true and median values are shown in Figure 3.5. The results show that the median 
values of R2t*, OEF, dCBV and Cdeoxy better represent the true values than the means because 
the histograms are skewed and the median is less biased by the outliers.  
 
Figure 3.6 The contour covariance maps of the simulated data. The results show the peak values 
of R2t* around 17, OEF around 40% and dCBV around 3%, well estimating the true values.  The 
covariance between OEF and dCBV is consistent with the actual covariance map between the 
OEF and dCBV presented in Fig. 6 in the previous publication by Ulrich and Yablonskiy (5). 
 
The 2D contour covariance maps of the relationships between R2t*, OEF and dCBV are shown 
in Figure 3.6. It demonstrates the peak value of R2t* around 17, OEF around 40% and dCBV 
around 3%, well estimating the true values. The negative correlation between R2t* and OEF (r = 
-0.88, p < 0.001) strengthens that the observed positive correlation between R2t* and OEFrel in 
our experimental data (Figure 3.3) reflects the physiological relationship instead of errors.  
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Figure 3.7 Typical example of the distribution of F(TE10) and the joint covariance contour of 
R2t* and F(TE10) are shown for a single subject. The range of F(TE10) is from 0 to 1 and most of 
values are between 0.9 to 1. The number of voxels with F(TE10) lower than 0.8 is quite small and 
they are not visible on the contour map. No covariance is found between R2t* and F(TE10) 
suggesting no bias in R2t* estimate due to the field inhomogeneities.  
 
The detailed analysis of the correction for field inhomogeneity artifacts was provided in 
Yablonskiy lab’s previous paper where voxel spread function method (3) was introduced. Here 
we further demonstrate that VSF procedure does not create bias in parameters estimates in our 
data. The signal decay due to the macroscopic field inhomogeneities is characterized by the F 
function at the last echo, F(TE10), where the strongest signal decay is observed.  Example of the 
distribution of F function at the last echo, F(TE10), and the contour map of the joint covariance 
between R2t* and F(TE10), for the whole gray matter from an individual subject is  shown in 
Figure 3.7. No correlation is found between R2t* and F(TE10). The peak value of F(TE10) is 
around 0.99 and most of values are located between 0.9 and 1 due to a good shimming procedure 
and rather small voxel size. The number of voxels with values lower than 0.8 is so small that 
they are not visible on the contour map. These voxels with lower F(TE10) are mostly affected by 
 55 
the magnetic inhomogeneity due to the air/water interface around the sinuses and represent a 
very small fraction of the brain.   
One additional bias in the parameter estimates may be related to the estimation of OEF. Because 
the BOLD model is developed under the assumption that the orientations of blood vessels are 
statistically random in each voxel, the actual variations of the blood vessel orientations may 
cause deviations in estimating OEF on a voxel by voxel basis. For example, if the blood vessels 
in some voxels have the predominant orientation parallel to the static magnetic field B0, the 
BOLD effect is so minimal that the fitting routine will substantially underestimate OEF; 
conversely, OEF will be underestimated for the voxels with the predominant orientations of 
blood vessels perpendicular to B0. However, as demonstrated in (8), the estimates of R2t* and 
dCBV are not affected by this limitation. Besides, the use of median values for representing our 
results for very large regions, also minimizes these biases.  
In conclusion, although substantial deviations from the true values of all parameters can be found 
in individual voxels and there are several restrictions on this model, the medians values of the 
parameters are very close to the true values. All in all, the simulations support that the 
methodology used in this study can generate the valid regional medians of R2t* and 
hemodynamic parameters for large cortical regions. In my dissertation, the results in cortical 
regions usually contain thousands of voxels. 
 
3.4 Discussion 
The result section shows the relationship between GEPCI derived parameters and age across 
cortical ROIs, which achieve the first goal of this study. The second goal is to interpret these 
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results and find out the biological meaning of GEPCI derived parameters, especially for R2* and 
R2t*. The key questions are: why R2t* increases with age in the cortex and what features of the 
brain cellular structure cause this increase and variability between different brain structures? 
Main contributions to R2t* signal decay in different brain structures come from the water 
molecules interactions with cell structural proteins, lipids and iron (80-82).  In the subcortical 
GM, i.e., the caudate, putamen and pallidum, a significant increase in R2* with age that we 
observed (Fig. 4), is consistent with previous studies (82-87) and is usually attributed to the 
known iron deposition in those regions with the increasing age. However, iron is unlikely a 
contributor to the age-related increase of the cortical R2t* because, according to Hallgren and 
Sourander (88), the iron content in the cortex remains nearly constant after the age of 30. The 
major contributions to the increased cortical R2t* and its variability are likely to be attributed to 
the water molecule interactions with other cellular structural components such as lipids and 
proteins.  
Another source of the variation in R2* potentially could be an anisotropic effect reported by 
Rudko et al (89). However, even at 9.4T field strength, R2* showed only 0.94 ± 0.32 s-1 
variation in GM of mice, which is a much smaller effect than the variation across different brain 
regions that we found in a human brain at 3T.  
The hypothesis that the changes of MR signal relaxation properties are related to the changes in 
the concentration of lipids and proteins has been useful in studying Central Nervous System 
(CNS) diseases, such as Multiple Sclerosis (e.g., (69, 90)) where cellular damage is mostly 
attributed to the loss of myelin. However, this hypothesis might not be adequate to describe 
normal aging effects of a healthy tissue where MR signal relaxation properties are related not 
only to the concentration of the cellular structural components but also to their cellular structural 
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arrangements (91). For example, lipids distributed as multiple small droplets would have much 
bigger water-accessible surface, hence cause substantially stronger relaxation effects than a 
single large lipid droplet with the same total amount of lipids. 
Herein by comparing our results with the literature data about normal aging (reviewed in Chapter 
2) we provide support for a hypothesis that in a healthy adult brain the tissue-specific R2t* can 
serve as a biomarker of the cortical “cellular packing density”, which is mostly proportional to 
the number of neurons and glial cells in the unit tissue volume.  We also use this hypothesis to 
explain the relationships between R2t* and the functional data, such as OEF and aerobic 
glycolysis.  
3.4.1  Cortical Cellular Packing Density is related to R2t* 
Our hypothesis is supported by the available literature data on the cellular changes in the aging 
brain. As reviewed in Chapter 2, it was a common impression that the neuron loss (20, 21) is an 
inevitable process of aging that leads to the cortical thinning and cognitive dysfunction. 
However, many studies have reported that the number of neurons in the human cortex remains 
the same over adult life (19, 22-26, 35, 92) and that normal aging is accompanied by changes in 
the dendritic structures, spine density and synapse density. Even the total number of glial cells in 
the cortex remains relatively constant over normal adult life (25, 27). The unchanged number of 
cells and the decreasing cortical volume imply the increasing cell density with age in the cortex, 
which is also supported by previous studies (23, 26, 31).  
This increasing age-related cortical cellular packing density in the cortex is consistent with our 
interpretation of age-related increased R2t* reported herein as a biomarker of cellular packing 
density. In this context, the product of R2t* and cortical thickness, SR2t*, represents the cellular 
packing content underneath a unit surface (e.g., 1 square millimeter surface) of the cortex. Our 
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finding that this product remains constant with age for all cortical regions (Figure 3.1g, Table 
3.1), is in agreement with the preservation of cortical cellular content in healthy adults over age.  
If both the number of neurons and the relative fraction of glial cells to neurons stay the same 
over age, the density of both neurons and glial cells would go up proportionally. Since axons and 
dendrites contain considerably larger concentration of macromolecules (e.g., lipids and proteins), 
their contribution to the R2t* relaxation is expected to be prevailing compared to glial cells even 
though concentration of glia cells in the cortex is higher. Hence, we hypothesize that the increase 
of R2t* is mainly due to the increased neuronal density.  
3.4.2  Neuronal Density of Non-human Primates is related to R2t* 
Our data is also compared with the neuronal density of non-human primates measured by Collins 
et al. (93). Collins et al. reported the highest neuronal density in primary visual cortex, the 
second highest in association visual areas and relatively higher density in primary somatosensory 
areas (S1) among all of the examined primates. Lowest neuronal densities were found in 
prefrontal cortex, premotor cortex or cortex ventral to S1 and motor cortex (M1) in different 
primates. Those distributions of neuronal density are in a good association with the distributions 
of R2t*. Indeed, the highest R2t* were found in the visual cortex (cuneus, lateral occipital and 
lingual) and the lowest were found in the frontal areas (Figure 3.2 and Table 3.1). Relatively 
higher R2t* were also shown in S1 and M1 (paracentral, precentral and postcentral) and R2t* 
values in these two regions were similar. Relatively lower R2t* were found in regions close to 
S1 and M1. All in all, these data further support our hypothesis that R2t* is related to neuronal or 
cellular packing density.  
Elston et al. (94) found that cells in the prefrontal cortex of humans are more branched and more 
spinous than those in the temporal and occipital lobes. Comparing these results with the 
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measurements of neuronal density by Collins et al. (93) we can conclude that regions with 
relatively lower neuronal density have more complex dendritic arbors, larger somas and dendritic 
field sizes and more spines than regions with higher neuronal density. This is in agreement with 
the line of consideration by Glasser and Van Essen (95) who utilized T1- and T2-weighted MRI 
to evaluate a distribution of the myelin content in the cortex. Hence, comparing the R2t* maps 
with these literature data (93, 94), we can further suggest that the areas with lower R2t* represent 
regions with complex dendritic arbors, larger somas and dendritic field sizes and more spines 
than regions with higher R2t*. 
3.4.3  Brain Tissue Hemodynamic Properties 
Besides R2t*, the relative OEF, dCBV and Cdeoxy are also derived from GEPCI data and they are 
in agreement with previous literature results. The distribution of the relative OEF in Figure 3.1 
shows the uniformity across frontal area and precuneus but higher values in the visual cortex 
(cuneus and lingual) which is consistent with the findings of default mode network (96). The 
relative OEF shows no significant change with age (Figure 3.2c), which is consistent with 
previous studies.  Leenders et al. reported that oxygen extraction fraction (OER) didn’t change or 
showed a slight increase with age in the selected regions (97). Pantano et al. showed that OEF 
had no statistically significant changes with age, although a small upward trend was present (98). 
Yamaguchi et al. also demonstrated that OEF didn’t show any correlation with age (99). GEPCI 
dCBV shows no significant change with age which is consistent with previous findings of no 
significant changes in the cerebral blood volume (which is a measure of both, dCBV and arterial 
blood volume) with age (97, 99).  
The R2t* map outlines practically the same pattern as the map of aerobic glycolysis (100) with 
areas of low R2t* corresponding to areas of high aerobic glycolysis and areas of high R2t* 
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corresponding to areas of low aerobic glycolysis. This fits well with our biophysical hypothesis 
of R2t* reflecting cellular packing density. Indeed, the areas of complex dendritic and synaptic 
structures characterized by lower R2t* are likely to require high aerobic glycolysis needed to 
support high synaptic activities (101). Moreover, since the correlation in brain regions between 
aerobic glycolysis and CBF is stronger than that between aerobic glycolysis and CMRO2 (101), 
areas of high aerobic glycolytic activity may show relatively lower OEF. Hence, it explains the 
strong correlation between R2* and OEF (p < 0.001, r = 0.71 in Figure 3.2b). It is also important 
to note that the regions with lower R2t* are mostly located within the default mode network (96). 
Although OEF and R2t* are derived from the same data and model, their correlation is robust. 
Computer Monte-Carlo simulations (15) demonstrated that bias in the estimation of R2t* due to 
using static dephasing regime model (11) does not exceed 0.3 s-1 and biases in OEF and dCBV 
are smaller than 10%. Furthermore, Figure 3.6 shows that the correlation between R2t* and 
OEFrel is negative due to the noise of the data and fitting routine. Hence, the observed positive 
correlation is due to the biological environment in the human brain. Besides, the results are 
consistent with the above listed literature data.  
 
3.4 Summary 
Distinguishing the cognitive changes of normal aging from the initial stages of 
neurodegenerative disorders, such as Alzheimer’s disease, can be difficult. Hence, establishing 
baseline MRI biomarkers for normal aging is significant and valuable. In this study, we used an 
advanced GEPCI approach (3-5) allowing the quantitation of various tissue specific structural 
and functional metrics.   
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Comparison between GEPCI data and the available literature information suggests that the age-
related increase in the cortical R2t* mostly reflect the age-related increase in the cellular packing 
density.  GEPCI data also show that tissue hemodynamic parameters, i. e. relative OEF, dCBV 
and Cdeoxy have no linear correlations with age and remain practically constant in most cortical 
regions. We found important correlations characterizing relationships between brain structural 
and hemodynamic properties in different brain regions. Specifically, thicker cortical regions have 
lower R2t*, reflecting less cellular packing density, and these regions extract less oxygen from 
the blood. 
All our findings can be understood if we put forward the following hypotheses: 
1. Regions in a brain characterized by a higher R2t* contain higher concentration of neurons 
with less developed cellular processes and are characterized by lower glycolytic activity. 
Accordingly, they require less blood flow to maintain their structure. These areas have higher 
OEF.  
2. Regions in a brain characterized by a lower R2t* represent regions with lower concentration of 
neurons but more developed cellular processes (dendrites, spines, etc.). They display higher 
glycolytic activity, hence require higher blood flow to maintain and develop new structural 
elements responsible for “information storage”. These areas have lower OEF.   
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Chapter 4: In vivo Detection of 
Microstructural Correlates of Brain 
Pathology in Preclinical and Early 
Alzheimer’s Disease with MRI 
 
4.1 Introduction 
Based on the biological interpretations of GEPCI metrics in Chapter 3, we now apply GEPCI 
metrics to Alzheimer’s disease (AD). As reviewed in Chapter 2, Alzheimer’s disease (AD) is a 
neurodegenerative disorder that is characterized by intraneuronal aggregates of tau called 
neurofibrillary tangles and extracellular aggregates of amyloid-beta (Aβ) protein called plaques. 
Clinically, AD is characterized by memory deficits and progressive cognitive impairment, 
leading to dementia. The preclinical stage of AD provides a large window for therapeutic 
intervention (102). Hence, one of the important directions is developing widely accessible 
neuroimaging techniques that can detect AD brain pathology in the preclinical stages (103, 104).  
One of the prevailing hypotheses of AD is the amyloid cascade hypothesis (36, 39, 41, 42) that 
suggests that abnormal accumulation of (Aβ) in the neocortex is one of the earliest pathological 
markers of AD. Paradoxically, it is also known that the medial temporal lobe (MTL), a region 
that mediates short-term memory, is affected early in the disease but is not the most affected 
region by Aβ deposition compared with neocortical regions (e.g., prefrontal cortex and precuneus 
(47-49)). At the same time, histological studies show that the MTL is particularly vulnerable to 
neurofibrillary pathology in the early stages of aging and AD (65, 66, 105-108). The reduction of 
volume and the loss of cells in the entorhinal cortex and hippocampus have been extensively 
reported in participants with mild cognitive impairment (MCI) and AD (57-61). Importantly, 
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neuropathology studies have established that symptomatic AD begins only when cell loss occurs 
in the hippocampal area (59).  
MRI is a potentially powerful tool to identify changes in the Alzheimer brain. Most MRI studies 
so far have focused on AD-related volumetric measurements of brain atrophy   (109). A few 
studies attempted to identify plaques via MRI in postmortem specimens or mice models (110-
115), though the latter methods require long imaging time and have not been translated to human 
studies.  
The goal of this study was to establish the relationship between GEPCI metrics and AD-related 
tissue damage at preclinical and very early symptomatic stages of AD. To this end, participants 
were enrolled from the Washington University Knight Alzheimer’s Disease Research Center 
(Knight ADRC) with well-characterized clinical status ranging from cognitively normal to very 
mild and mild AD, and with a battery of psychometric, CSF and neuroimaging data. We 
demonstrated a significant correlation between GEPCI metrics of brain tissue cellular damage in 
the hippocampus and cognitive performance. Importantly, this correlation is stronger than the 
correlation between cognitive performance and hippocampal atrophy, thus suggesting that the 
integrity of the remaining tissue is a more important parameter for brain functioning than the loss 
of tissue volume alone. We also uncovered a remarkable correlation between GEPCI metrics and 
beta-amyloid load measured by positron emission tomography (PET) (the current in vivo gold 
standard), thus supporting GEPCI as a potential surrogate marker for Aβ imaging in preclinical 
and early Alzheimer disease. 
The results demonstrate that GEPCI is sensitive to early AD-related pathological changes in 
brain tissue. Since the GEPCI approach is based on MRI that is widely available worldwide, is 
non-invasive, and does not require radiation exposure, it can open opportunities to obtain new 
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information on the pathogenesis of AD. The new method can also open the door for screening 
cohorts for clinical drug trials (stratification) that are enrolling individuals with preclinical or 
early symptomatic AD. 
 
4.2 Methods 
4.2.1  Participants 
This study was approved by the Institutional Review Board of Washington University School of 
Medicine (WUSM). 34 participants were selected from the studies of aging and dementia at the 
Knight Alzheimer’s Disease Research Center (ADRC) at WUSM. All participants provided 
informed consent. All participants in this study underwent a collection of cognitive performance 
tests (116), including Free and Cued Selective Reminding Test (Srtfree), Animal Naming 
(ANIMALS), and Trail making Test Part A (Tma) . Cognitive status was operationalized with 
the Clinical Dementia Rating (CDR) (67), as determined by Knight ADRC clinicians according 
to standard protocols; diagnoses were in accordance with standard criteria (38). The participants 
were assessed to be cognitively normal (CDR = 0) or to have mild (CDR = 0.5 or 1) AD 
dementia. 19 participants underwent PiB PET imaging to estimate amyloid deposition in the gray 
matter and white matter of their brains. The measurements of CSF biomarker Aβ42 (INNOTEST, 
Fujirebio, Gent, Belgium) were available for 31 participants. For participants that underwent PiB 
PET imaging, amyloid positivity was defined by a cutoff of mean cortical binding potential 
(MCBP)=0.18 (117) which corresponds to a mean cortical standardized uptake value ratio (MC-
SUVR) of 1.3 referenced to cerebellar grey matter. MC-SUVR for Aβ imaging is calculated as 
the averaged SUVR of regions within the prefrontal cortex, gyrus rectus, lateral temporal, and 
precuneus regions. For participants that did not have PET Aβ measurements, Aβ positivity was 
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determined by the status of their CSF biomarker Aβ42 (103). According to the Aβ status, 
cognitively normal participants (CDR = 0) were further divided into normal (CDR = 0; Aβ 
negative) and preclinical (CDR = 0; Aβ positive) groups. Notice that one participant with CDR = 
0.5 and one with CDR = 1 had negative Aβ status. Demographic information for all groups is 
presented in Table 4.1. 
 
 
 
 
 
 
 
Table 4.1 Distribution of participants between groups and their demographic information. Note 
that nine participants in Mild AD group were Aβ positive and two were Aβ negative. 
 
4.2.2  MRI Data Acquisition 
All participants were scanned in a 3T PET-MR scanner (Siemens, Erlangen, Germany). A 3D 
multi gradient echo sequence was used to obtain the data. Sequence parameters were: resolution 
1×1×2 mm3 (read, phase, slab), FOV 256 mm×192 mm, repetition time TR = 50ms, flip angle 
30°, 10 gradient echoes with first gradient echo time TE1 = 4 ms, echo spacing ∆TE = 4ms. 
Additional phase stabilization echo (the navigator data) was collected for each line in k-space to 
correct for image artifacts due to the physiological fluctuations (4). The total acquisition time of 
GEPCI was 11 mins 30s. Macroscopic field inhomogeneity effects (background gradients) were 
accounted for by using the voxel spread function (VSF) approach (3). Standard clinical 
Magnetization-Prepared Rapid Gradient Echo (MPRAGE) (75) images with TR/TI/TE = 
Table 4.1 
 Normal Preclinical AD Mild AD 
 CDR=0 
Aβ negative 
CDR=0 
Aβ positive 
CDR=0.5 
or 1 
N 13 10 11 (7/4) 
Age 69.6±8.7 72.3±8.4 76.0±8.4 
Female/Male 7/6 4/6 3/8 
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2200/1100/3.37 ms and the resolution 1×1×1 mm3 were also collected for segmentation 
purposes. The total acquisition time of MPRAGE is 6 mins. 
4.2.3  Data Analysis and GEPCI Images Generation 
This part was the same as Chapter 3, which was described in details in Chapter 1. Herein, I 
briefly introduce the model and fitting parameters: 
            
 *0 1 1
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0 1 1
( ) exp 2 ( ) 2 ( ( )
( ) exp 2 ( ) 2 ( ) ( ) ( )BOLD
S TE A R TE TE i f TE TE F TE
S TE A R t TE TE i f TE TE F TE F TE


          
             
       (4.1)     
where TE is the gradient echo time, R2*=1/T2* is the global transverse relaxation rate constant, 
R2t*=1/T2t* is the tissue transverse relaxation rate constant in the absence of BOLD effect, Δf is 
the frequency shift (dependent on tissue structure and also macroscopic magnetic field created 
mostly by tissue/air interfaces), function ( )BOLDF TE  describes GRE signal decay due to the 
presence of blood vessel network with deoxygenated blood, and function F(TE) describes the 
effects of macroscopic magnetic field inhomogeneities. 
By fitting the equation to the real and imaginary parts of the complex signal using nonlinear 
regression algorithm, six parameters are computed: A0 (T1-weighted), R2*, R2t*, Δf,  and   
for each voxel in the brain. In this study, we focus on total R2* and tissue specific R2t* 
measurements for quantifying tissue microstructural properties and GEPCI T1W images (the 
square root of parameter A0) for brain structure delineation and segmentation.  
Notice that ( )BOLDF TE  in Equation 4.1 was originally designed to describe the signal decay due 
to the presence of different types of magnetic susceptibility inclusions, such as  blood vessel 
network (BOLD effect), trabecular bone and iron oxide nanoparticles, etc. (11). It has different 
formulas for different inclusions and the one we used in this study is modeled for the blood 
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vessel network. But in the context of AD, ( )BOLDF TE  may also include the mesoscopic 
inhomogeneity effects created by amyloid plaques that are known to create R2* signal decay 
(115). As a result, R2* is more related to the amyloid deposition while R2t* is more related to 
the tissue structure. 
4.2.4  Image Segmentation 
The segmentation part is also the same as Chapter 3. FreeSurfer software  (Laboratory for 
Computational Neuroimaging, Martinos Center for Biomedical Imaging) (76) was used to 
generate brain segmentations, cortical thicknesse and volume based on MPRAGE images. Then, 
MPRAGE images are registered to GEPCI-T1-weighted (T1W) images using FMRIB’s Linear 
Image Registration Tool (77, 78) in FSL and the transformation matrices of the registration are 
generated. Finally, these matrices were applied to the brain segmentations from FreeSurfer and 
transformed to the space of GEPCI-T1W images. One of the important advantages of GEPCI is 
that all GEPCI images are generated from a single MRI scan and are naturally co-registered. 
Hence, segmentations of GEPCI T1W images were naturally co-registered with all other GEPCI 
maps.  
A CSF mask from FSL is further applied removing voxels in CSF on FreeSurfer segmentations. 
To maximize accuracy of measurements, statistical results instead of voxel-wise analysis are 
reported: for each FreeSurfer region containing thousands of voxels, a single parameter – mean 
value of GEPCI parameter, is generated. 
 
4.3 Results and Discussions 
In the context of AD, we hypothesize that the increased beta-amyloid deposition should lead to 
an increase in GEPCI R2* that is sensitive to mesoscopic field inhomogeneities (8, 11). The 
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mesoscopic field inhomogeneities may be  present around amyloid deposits and can be enhanced 
due to the presence of iron in amyloid plaques (111). On the other hand, cellular loss 
characteristic of AD can lead to decreased GEPCI metrics, especially R2t* that is sensitive to 
cellular structure (12). The interplay between these two opposing processes can define important 
features of the GEPCI signal in AD. 
4.3.1  Correlation between R2* and PiB-PET Aβ Measurement 
 
Figure 4.1 Correlation between PiB PET Aβ SUVR (dimensionless) and R2* (s-1) relaxation rate 
constant obtained in 19 participants. Plots show examples of correlation in several brain regions. 
Each point represents a single participant. Shaded areas represent 95% confidence intervals of 
the linear fits (solid lines). Pearson correlation coefficients (r) and p values (corrected for 
multiple comparison using false discovery rate over all cortical regions) are shown in the left 
upper corners. The surface maps on the right represent r values in all cortical areas. The image 
segmentation is based on the FreeSurfer software (76). The data show significant correlations not 
only in the areas of high Aβ accumulation (e.g., precuneus) but also in the areas of MTL, such as 
the parahippocampal cortex and the fusiform cortex. Particularly, the strongest and most 
significant correlation exists in the parahippocampal cortex. 
 
The correlation analysis between R2* and PiB PET Aβ measurements (using standardized uptake 
value ratio [SUVR]) revealed positive correlations in most cortical brain regions. The data 
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showed significant correlations not only in the areas of high Aβ accumulation (e.g., precuneus) 
but also in the areas of MTL, such as the parahippocampal cortex and the fusiform cortex. But 
not all correlations were statistically significant after correction for multiple comparison using 
false discovery rate (FDR) (118), most likely due to the small sample size (PiB PET data were 
available only for 19 participants). Examples of the correlations with significant p values are 
shown in Figure 4.1.  
The strongest correlation between R2* and Aβ SUVR that we found in the parahippocampal 
cortex shows the high sensitivity of GEPCI R2* to Aβ accumulation in this area. Interestingly, 
although the range of SUVR in parahippocampal cortex is smaller than in precuneus, the 
correlation in parahippocampal cortex is much stronger than that in precuneus. It indicates that 
even though MTL is not the area of the highest burden of Aβ in the AD brain, it represents a very 
important area of pathological changes in early AD particularly as it relates to the formation of 
Aβ plaques in the cerebral cortex, where the changes can be detected by GEPCI R2*. This 
feature likely can be attributed to distinct cellular properties of the gray matter in the MTL that 
play important roles in functionally connecting the neocortex and hippocampus (119). 
Structurally, the parahippocampal gyrus is a transitional zone, where the entorhinal cortex 
(referred as perialocortex) contains the lamina dissecans while the perirhinal and 
parahippocampal cortexes (referred as proisocortex) have their cellular structure different from 
the major three-layered and six-layered cortex areas (120). As different cellular components and 
arrangements contribute to R2*, it is possible that the strong correlations between R2* and Aβ 
SUVR in the parahippocampal cortex is due to its unique laminar organizations. Since the medial 
portion of the fusiform gyrus is also considered to be part of the parahippocampal cortex, it is 
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reasonable to observe the significant correlation between R2* and Aβ SUVR in the fusiform as 
well.  
How can we interpret the correlation? As we discussed in Methods, ( )BOLDF TE  may also include 
the mesoscopic inhomogeneity effects created by amyloid plaques that are known to create R2* 
signal decay (115). Since no correlation exists between amyloid accumulation and BOLD effect 
(100), the correlation between amyloid accumulation and R2* is mostly related to magnetic 
susceptibility effects created by amyloid plaques. A hypothesized iron deposition in amyloid 
plaques (111, 121) could lead to additional sensitivity of GEPCI R2* to Aβ accumulation. 
The presence of neurofibrillary tangles (NFTs) and neuronal loss in the parahippocampal gyrus 
previously reported by Thangavel et al (65) can also affect R2*. However, their participants were 
assessed at death after nearly a decade of dementia, while the cohort in this study represents 
mostly normal, pre-symptomatic, very mild (CDR = 0.5) or mild (CDR=1) AD. In addition, as 
tissue damage in the parahippocampal gyrus was smaller than that in the hippocampus (66), in 
our cohort the loss of neurons in the parahippocampal gyrus may not be severe enough to affect 
R2* measurements.  
Even though the significance of the correlations between R2* and Aβ SUVR vary for different 
brain regions, R2* in the parahippocampal cortex can still be used for evaluation of Aβ burden in 
all regions. Indeed, the data show very strong correlations between Aβ SUVR in most cortical 
regions and R2* values in the parahippocampal cortex. These correlations can be described as 
follows:  
                                                    
* *( 2 2 )ROI ROI ROI PH PHSUVR a k R R                                 (4.2)                                                                          
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and can be used for evaluation of Aβ SUVR for a given participant in any cortical region. In 
Equation (4.2), 
*2PHR  is 
*2R  in the parahippocampal cortex for a given participant, and 
*2PHR  = 
16.55 sec-1, is the mean value of R2* in the parahippocampal cortex of the normal control group 
(9 participants with negative PiB Aβ and CDR = 0). The coefficients ROIa  and ROIk in Equation 
(4.2), specific for each cortical ROI, are provided in Table 4.2 along with the results of the 
correlations. 
*2PHR  is introduced in Equation (4.2) to make the coefficients ROIa  of the regression 
more meaningful – they represent region-specific averaged SUVR for healthy control group. The 
slopes of the regression (parameter ROIk ) are also shown in Figure 4.2, upper row. The spatial 
pattern in Figure 4.2 is similar to previously established correlation pattern between regional and 
mean values of PiB SUVR (122). Hence, the data demonstrate that R2* in the MTL (especially 
the parahippocampal cortex) not only correlate with PiB PET SUVR in this area but also 
strongly correlate with PiB PET SUVR throughout the entire cortex.  
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Table 4.2 
Cortical area Intercept (a) Slope (k, sec) p value r 
bankssts 1.35 0.24 2.47E-04 0.75 
caudal-anteriorcingulate 1.23 0.27 2.45E-04 0.75 
caudal-middlefrontal 1.16 0.24 1.76E-04 0.76 
cuneus 1.22 0.12 2.79E-02 0.50 
entorhinal 1.10 0.08 1.33E-04 0.77 
frontalpole 1.07 0.30 5.31E-04 0.72 
fusiform 1.21 0.15 2.02E-04 0.75 
inferiorparietal 1.21 0.23 4.08E-04 0.73 
inferiortemporal 1.15 0.20 4.63E-04 0.72 
insula 1.23 0.18 2.90E-04 0.74 
isthmuscingulate 1.34 0.25 5.46E-04 0.72 
lateraloccipital 1.15 0.12 1.22E-03 0.68 
lateralorbitofrontal 1.26 0.25 4.45E-04 0.72 
lingual 1.19 0.12 6.46E-03 0.60 
medialorbitofrontal 1.23 0.32 2.98E-04 0.74 
middletemporal 1.13 0.21 1.73E-04 0.76 
paracentral 1.21 0.23 1.00E-03 0.69 
parahippocampal 1.11 0.15 6.09E-06 0.84 
parsopercularis 1.19 0.23 4.66E-04 0.72 
parsorbitalis 1.13 0.26 4.97E-04 0.72 
parstriangularis 1.20 0.24 3.90E-04 0.73 
pericalcarine 1.27 0.14 2.56E-02 0.51 
postcentral 1.07 0.15 2.02E-03 0.66 
posteriorcingulate 1.29 0.32 4.58E-04 0.72 
precentral 1.14 0.14 9.57E-04 0.70 
precuneus 1.30 0.32 5.93E-04 0.71 
rostralanteriorcingulate 1.23 0.31 2.28E-04 0.75 
rostralmiddlefrontal 1.16 0.30 4.34E-04 0.73 
superiorfrontal 1.14 0.28 3.25E-04 0.74 
superiorparietal 1.15 0.21 6.31E-04 0.71 
superiortemporal 1.15 0.18 2.45E-04 0.75 
supramarginal 1.16 0.21 6.68E-04 0.71 
temporalpole 1.11 0.10 9.94E-04 0.69 
transversetemporal 1.21 0.18 4.48E-04 0.72 
Table 4.2. The results of linear regression analysis of the relationship between regional amyloid 
SUVR in different cortical regions and the parahippocampal R2*. Cortical regions are selected 
based on the FreeSurfer segmentation (76). The data show coefficients of linear regression  in 
Equation (4.2) and the correlation coefficients (r). The mean value of R2* in the 
parahippocampal region for the control group in Equation 4.2 is 16.55 sec-1. 
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Figure 4.2 Upper row represents the surface maps of the slopes (units of sec) of linear regression 
(coefficient ROIk  in Equation (4.2)) between regional PET-measured Aβ SUVR and 
parahippocampal R2* across 19 participants. All regional slopes are positive. The coefficients of 
the linear regressions are listed in Table 4.2. The second and the last rows represent the averaged 
cortical mean values of R2* and Aβ SUVR across the same 19 participants. White matter, deep 
gray matter and ventricles were excluded. The image segmentation is based on the FreeSurfer 
software (76). 
 
While the data show rather significant positive correlations between R2* and amyloid burden 
across the participants in different brain regions (Figure 4.1), there also exists an inverse 
association across the brain regions between averaged R2* and amyloid distributions. Figure 4.2 
shows regional R2* and Aβ SUVR averaged across 19 participants mapped onto the brain 
surface. Lower R2* are found in the frontal cortex, posterior cingulate, precuneus, 
parahippocampal cortex, entorhinal cortex and superior temporal cortex. Higher R2* are found in 
the occipital cortex, paracentral cortex, fusiform, middle and inferior temporal cortex. This R2* 
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distribution is consistent with the previous studies (12). In contrast to the R2*, the PiB retention 
was prominently higher in the frontal cortex, posterior cingulate, precuneus and inferior parietal 
cortex, which is also consistent with the previous reports (44, 47). Generally speaking, PiB Aβ 
binding tends to increase in the regions with lower R2*, which may indicate that the regions with 
lower R2* are more vulnerable to the amyloid accumulation. This relationship is more obvious 
in the frontal cortex, posterior cingulate, precuneus, inferior parietal cortex characterized with 
higher SUVR but lower R2*, and occipital cortex with lower SUVR but higher R2*. 
Interestingly, the former regions mostly overlap the default mode network (96) and tend to be 
both structurally and functionally vulnerable in normal aging and Alzheimer’s disease, which 
was suggested to be due to a high degree of life-long plasticity (32). The R2*- Aβ association 
points to an important relationship between brain microstructural properties reflected in tissue 
specific R2* measurements and the relationships between default activity, amyloid, and memory 
previously reported by Buckner et al (123). It is also in agreement with our previous 
consideration (12) that the cortical areas with lower R2t* (e.g., prefrontal cortex) may have more 
complex dendritic and synaptic structure, which may also be related to the neuroplasticity and 
AD vulnerability. From this perspective, the parahippocampal and entorhinal cortices, which are 
primary memory-related areas and are vulnerable to early Alzheimer, are also characterized by a 
lower baseline R2*. However, PiB retention and Aβ accumulation in these areas are not 
prominent. Nevertheless, the correlation between GEPCI R2* metrics and PiB retention in these 
areas is exceptionally strong, especially in the parahippocampal gyrus.  
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4.3.2  R2* Differentiates Normal and Preclinical AD Participants 
 
 
 
 
 
 
 
Figure 4.3 Group comparison based on R2* in the parahippocampal cortex. The bar graph on the 
left shows significant differences between participants with the negative (n = 15, R2* = 16.79 ± 
1.40 s-1) and the positive (n = 19, R2* = 18.20 ± 1.08 s-1) Aβ status. The bar graph on the right 
shows significant differences between the normal group (CDR = 0, Aβ negative, n=13, R2* = 
16.77 ± 1.51 s-1) and the preclinical group (CDR = 0, Aβ positive, n = 10, R2* = 18.41 ± 0.84 s-
1). 
  
Based on the strong correlation between Aβ SUVR and R2* in the parahippocampal cortex, R2* 
can potentially be used to distinguish the healthy stage from the preclinical AD as early AD is 
associated with Aβ accumulation (36, 39, 41, 42). Indeed, the bar graph on the left in Figure 4.3 
shows a significant difference in the parahippocampal R2* between all participants with negative 
(n = 15) and positive (n = 19) Aβ status (independent of CDR, see definition in Methods). The 
bar graph on the right shows significant differences between normal group (CDR = 0, amyloid 
negative, n=13) and preclinical group (CDR = 0, Aβ positive, n = 10).  
4.3.3  Correlation between R2t* and Cognitive Performance Tests 
In Chapter 3, we compared GEPCI-derived tissue specific structural and functional metrics with 
existing literature and hypothesized that the parameter R2t* is related to the tissue neuronal 
density (12). As presented in the scatter plots in Figure 4.4, R2t* in the hippocampus was 
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associated with the free recall condition of the Free and Cued Selective Reminding Test (Srtfree; 
r = 0.53, p = 0.002), with the total correct score from the Animal Naming test (ANIMALS; r = 
0.50, p = 0.0025), and with the Trailmaking Test Part A completion time (Tma; r = -0.47, p > 
0.017). The decrease of R2t* is related to the neuronal damage in the hippocampus and so 
corresponds to a bad cognitive performance. But R2t* in the cortex doesn’t significantly 
correlate with these three cognitive tests. This may be because the participants were 
characterized either as cognitively normal or having mild cognitive impairment (MCI), the 
neuronal damage (decreased R2t*) occurs first in the hippocampal area but may not spread to the 
cortical areas yet. 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 Correlation between cognitive tests performance and hippocampal R2t*. Cognitive 
measures included Free and Cued Selective Reminding Test (Srtfree), Animal Naming 
(ANIMALS), and Trail making Test Part A completion time (Tma). Note that higher scores on 
Tma indicate worse performance. Correlations with hippocampal volume are also presented for 
comparison. Each point represents a single participant (n = 34). Shaded areas represent 95% 
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confidence intervals of linear fits (solid lines). Pearson correlation coefficients (r) and p values 
are shown in the left upper corners.  
 
Note that considerably weaker correlations were found between hippocampal volume and 
cognitive performance (Figure 4.4, second column), suggesting that the integrity of the 
remaining hippocampal tissue (characterized by R2t*) is a more important parameter of 
hippocampal pathology than hippocampal volume.  
No significant correlation was found between cognitive performance and R2* or CSF Aβ42. This 
result is in agreement with the dissociation between PiB defined Aβ plaques and cognitive 
performance (124-128).  At least 30% of people with significant Aβ burden are cognitively 
normal (124).  
4.3.4 R2t* Distinguishes Cognitively Normal Group from Mild AD Group 
Figure 4.5 shows examples of three participants’ GEPCI images from healthy control, preclinical 
and mild AD groups. Thin contours outline the hippocampus determined by FreeSurfer. In all 
cases, MPRAGE and GEPCI T1w images show small atrophy progressing from healthy to AD 
group. Gradually decreased R2t* suggest altered tissue integrity even in the preserved 
hippocampal area. One should keep in mind that GEPCI metrics (R2* and R2t*) are quantitative 
and provide information on tissue integrity based on comparison with healthy control 
measurements, thus uncovering tissue damage that might not be simply visible on images. 
Though tissue damage in the hippocampus can be clearly seen as hypointense signal on R2t* 
maps. 
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Figure 4.5 Examples of three participants’ images – 69 year old female from the control group 
(upper row), 72 year old male from the preclinical AD group (second row) and 69 year old male 
from the mild AD (CDR = 0.5) group. Thin contours outline the hippocampus determined by 
FreeSurfer. In all cases, MPRAGE and GEPCI T1w images show small atrophy progressing 
from healthy to AD group. Gradually decreased GEPCI R2t* suggest altered tissue integrity even 
in the preserved hippocampal area. 
 
The bar graphs in Figure 4.6 show group comparisons based on R2t* in the hippocampus. Three 
groups are shown - normal participants (CDR = 0, Aβ negative), preclinical group (CDR = 0, Aβ 
positive) and mild AD (CDR = 0.5 or 1). The first box shows results for tissue R2t* and the 
second block shows results for hippocampal volume. The significantly decreased hippocampal 
volume in mild AD group is in agreement with known brain atrophy characteristic for AD (109).  
While changes in R2t* likely reflect changes in the neuronal and synaptic density, it may also 
reflect changes in other tissue components. Hypothetically, the slight but not significant increase 
in tissue R2t* seen in preclinical group as compared to normal participants in Figure 4.6 and 
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Table 4.3 may be attributed to accumulation of tau protein as in early Braak stages (105) of AD. 
Interestingly, Figure 4.6 and Table 4.3 also show that the hippocampal volume in the preclinical 
group was also slightly but not significantly higher than that in the normal group.  
 
Figure 4.6 Bar graphs show the data obtained in the hippocampus of 34 participants. Bars 
represent mean values and error bars are standard deviations. Data are separated into three 
groups: Normal, preclinical AD, and mild AD (CDR 0.5 or 1). GEPCI R2t*, and volumes are 
shown. Also shown is the parameter TCI (tissue content index, Equation (4.3)). While R2t* can 
serve as a surrogate marker of neuronal density/integrity, the TCI can serve as a surrogate marker 
characterizing a change in the total neuronal content. The results are summarized in Table 4.3. 
 
 
 
 
 
 
 
Table 4.3. The mean and standard deviations of R2t*, volume and TCI in hippocampus over 
three groups presented in Figure 4.6. 
 
 
Table 4.3 
 R2t*(s-1) Volume(mm3) TCI 
Normal 11.71 ± 1.45 3512 ± 327 0.00 ± 0.16 
Preclinical 12.20 ± 1.50 3720 ± 452 0.11 ± 0.22 
Mild AD 9.94 ± 1.38 2849 ± 552 -0.31 ± 0.16 
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If R2t* is related to neuronal density/integrity, the product of R2t* and the hippocampal volume 
(V) could characterize the total neuronal content in the hippocampus. Hence, to characterize the 
global tissue change in the hippocampus, it is convenient to introduce the Tissue Content Index 
(TCI): 
                                                    
* *
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( 2 ) ( 2 )
( 2 )
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control
V R t V R t
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V R t
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
                                      (4.3)       
where 
*( 2 )controlV R t  = 41201 mm
3·sec-1 is a mean value of tissue content in the group of 
normal participants. The changes in the TCI between Normal, Preclinical and AD groups are 
shown in the third box of Figure 4.6. 
The results in Figure 4.6 show that not only does the hippocampal tissue volume reduce in mild 
AD participants, but R2t* also reduces. As a result, the TCI reduce even more significantly. 
These results are in a full agreement with the histopathological studies  of Price, Morris and co-
workers (59) who found that 46% of neurons were lost in the hippocampus of people with CDR 
= 0.5 as compared to cognitively normal participants, while the hippocampal volume loss was 
only 29%. Comparison of our findings with direct neuronal measurements in (59) further 
confirms our hypothesized relationship between  R2t* and  neuronal density. The decreased R2t* 
and TCI is consistent with decreased tissue neuronal density and the tissue neuronal content in 
the hippocampus. Furthermore, no significant differences in hippocampal R2t*, volume and TCI 
between the normal and preclinical AD groups, is also consistent with Price, Morris and co-
workers’ finding of no significant difference in hippocampal neuron number and volume 
between the normal and preclinical AD groups (59).  
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4.4 Summary 
In this study, we have demonstrated that the GEPCI technique provides a new approach to the in 
vivo evaluation of pathology in the preclinical and early symptomatic stages of AD. It is based 
on a multi-gradient-echo MRI sequence that is available from most MRI manufacturers. GEPCI 
data are quantitative, reproducible and MRI scanner independent, thus allowing multi-center 
applications. The results show that GEPCI metrics are good correlates of Aβ accumulation and 
neurodegeneration. They are sensitive enough to distinguish between normal individuals and 
those with preclinical (asymptomatic) and early symptomatic AD.  
One of the significant conclusions of this study is that the tissue cellular integrity of the 
preserved part of the hippocampus is a more important parameter affecting cognitive 
performance than the hippocampal atrophy. This points out to the presence of significant 
cognitive reserve in the hippocampal structure. Another important finding is that the AD 
symptoms do not start until there has been significant cellular loss in the hippocampus identified 
by GEPCI metrics, consistent with Price, Morris and colleagues (59).   
Since MRI is a much more available modality than PET (current imaging “gold standard” for in 
vivo quantifying AD (Aβ) brain pathology), and poses fewer risks, GEPCI metrics (R2* and 
R2t*) have a potential for improving the quality of AD diagnostic measures, and the evaluation 
of new disease-modifying therapies.  
The results of this study are based on data obtained from 34 participants. Larger and independent 
samples certainly should be used to further validate our findings. 
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Chapter 5: Future Plan 
 
Last but not least, the GEPCI approach has been used to study many cognitive disease. For 
example, GEPCI has been used to identify brain tissue damage in multiple sclerosis (2, 4, 69-72) 
and psychiatric diseases (73). R2* has been found to be significantly lower in patients with 
multiple sclerosis (MS) than in healthy participants (2, 4, 69-72). Significant correlations 
between age-adjusted R2* and clinical scores of MS have been reported for cortical regions (71). 
Significant group effects based on GEPCI metrics have been observed in the superior temporal 
cortex and in the thalamus of the participants with schizophrenia and bipolar disorder (73). In 
this dissertation, the GEPCI approach has been applied to normal aging and Alzheimer’s disease. 
Thus, there is a potential for the GEPCI approach to provide insightful information about 
cognitive disease. Certainly, more experimental data should be investigated to validate this 
approach. The following ideas may be considered as future directions: 
1. More participants with various amounts of amyloid deposition should be recruited to 
further validate the correlation between the PET biomarker retention of amyloid 
deposition and GEPCI R2*. 
2. More participants with CDR = 0, 0.5, and 1 should be recruited to further validate the 
correlation between the cognitive performance tests and the GEPCI hippocampal R2t*, 
and to further validate the ability of R2t* to distinguish cognitively normal and mild AD 
groups. 
3. A recent study reports the detection of tau deposition in vivo using PET imaging (54). 
Similar correlations between PET biomarker retentions of tau and GEPCI metrics (e.g., 
R2* and R2t*) should be investigated.  
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4. Examine the autopsy of participants who underwent GEPCI MRI prior to expiration. 
Also investigate the histological results and GEPCI results. For example, investigate the 
relationship between neuronal density and GEPCI R2t*.  
5. Interestingly, supervised machine-learning classification and cross-validation algorithms 
may be applied to quantitative GEPCI measurements to classify volunteers’ condition 
with respect to Alzheimer’s disease if a large dataset is available. Because deep learning 
has been widely used in image processing, it is interesting to apply deep-learning 
algorithms directly to MRI images for classification.  
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